Search

Your search keyword '"Sainsous, J."' showing total 42 results
Start Over Author "Sainsous, J."
42 results on '"Sainsous, J."'

2. Abstracts

Author

Barthelemy, O., primary, Silvain, J., additional, Brieger, D., additional, Bellemain-Appaix, A., additional, Cayla, G., additional, Beygui, F., additional, Lancar, R., additional, Collet, J. P., additional, Mercadier, A., additional, Montalescot, G., additional, Cha, K. S., additional, Nam, Y. H., additional, Kim, J. H., additional, Park, S. Y., additional, Park, T. H., additional, Kim, M. H., additional, Kim, Y. D., additional, Lee, H. C., additional, Ahn, M. S., additional, Hong, T. J., additional, Blanco, R., additional, Blanco, F., additional, Szarfer, J., additional, Garcia Escudero, A., additional, Gigena, G., additional, Gagliardi, J., additional, Rodriguez, A., additional, Sarmiento, R., additional, Affatatto, S., additional, Riccitelli, M., additional, Petris, A., additional, Datcu, M. D., additional, Pop, C., additional, Radoi, M., additional, Arsenescu-Georgescu, C., additional, Petrescu, I., additional, Petrescu, L., additional, Serban, L., additional, Nechita, E., additional, Tatu-Chitoiu, G., additional, Dorobantu, M., additional, Benedek, I., additional, Craiu, E., additional, Sinescu, C., additional, Ionescu, D. D., additional, Ginghina, C., additional, Minescu, B., additional, Izzo, A., additional, Mantovani, P., additional, Tomasi, L., additional, Dall'oglio, L., additional, Bonatti, S., additional, Rosiello, R., additional, Romano, M., additional, Agostini, F., additional, Zanini, R., additional, Zhao, Z. Y., additional, Wu, Y. J., additional, Li, J. J., additional, Yany, Y. J., additional, Qian, H. Y., additional, Tang, Y. D., additional, Timoteo, A. T., additional, Toste, A., additional, Lousinha, A., additional, Ramos, R., additional, Oliveira, J. A., additional, Ferreira, M. L., additional, Ferreira, R. C., additional, Cabades, C., additional, Diez Gil, J. L., additional, Aguar, P., additional, Sanmiguel, D., additional, Lopez-March, A., additional, Marmol, R., additional, Guerra, L., additional, Girbes, V., additional, Ferrando, J., additional, Rincon De Arellano, A., additional, Patricio, L., additional, Blondal, M., additional, Ainla, T., additional, Marandi, T., additional, Eha, J., additional, Oliveira, M. M., additional, Silva, M. N., additional, Cunha, P. S., additional, Feliciano, J., additional, Silva, S., additional, Kanovsky, J., additional, Kala, P., additional, Parenica, J., additional, Poloczek, M., additional, Prymusova, K., additional, Kubkova, L., additional, Spinar, J., additional, Olinic, D., additional, Homorodean, C., additional, Ober, M., additional, Olinic, M., additional, Andrioaia, C., additional, Condac, A., additional, Masmoudi, M., additional, Berdaoui, B., additional, Labidi, S., additional, Tapia Ballesteros, C., additional, Hernandez Luis, C., additional, Sandin, M. G., additional, Vegas, J. M., additional, Andion, R., additional, Martinez, N., additional, Gonzalez, I. A., additional, Alvarado, M., additional, Amat, I. J., additional, San Roman, J. A., additional, Garcia Gonzalez, M. J., additional, Arroyo Ucar, E., additional, Hernandez Garcia, C., additional, Dorta Martin, M., additional, Marrero Rodriguez, F., additional, Dragu, R., additional, Kapeliovich, M., additional, Hammerman, H., additional, Silva, D., additional, Cortez-Dias, N., additional, Jorge, C., additional, Silva Marques, J., additional, Carilho Ferreira, P., additional, Robalo Martins, S., additional, Almeida Ribeiro, M., additional, Calisto, C., additional, Fiuza, M., additional, Lopes, M. G., additional, Milicevic, P., additional, Panic, M., additional, Stankovic, I., additional, Milicevic, D., additional, Kalezic, T., additional, Kafedzic, S., additional, Ilic, I., additional, Cerovic, M., additional, Putnikovic, B., additional, Neskovic, A., additional, Rott, D., additional, Leibowitz, D., additional, Monhart, Z., additional, Reissigova, J., additional, Grunfeldova, H., additional, Jansky, P., additional, Valente, B., additional, Villanueva Benito, I., additional, Solla, I., additional, Paredes, E., additional, Diaz Castro, O., additional, Calvo, F., additional, Baz, J. A., additional, Iniguez, A., additional, Aleksova, A., additional, Gerloni, R., additional, Belfiore, R., additional, Carriere, C., additional, Barbati, G., additional, Fabris, E., additional, Possa, F., additional, Nait, D., additional, Milo, M., additional, Sinagra, G., additional, Marques, N., additional, Mimoso, J., additional, Gomes, V., additional, Agra Bermejo, R. M., additional, Emad Abu Assi, E. A. A., additional, Sergio Raposeiras Roubin, S. R. R., additional, Pilar Cabanas Grandio, P. C. G., additional, Carlos Pena Gil, C. P. G., additional, Jose Maria Garcia Acuna, J. M. G. A., additional, Jose Ramon Gonzalez Juanatey, J. R. G. J., additional, Daly, M. J., additional, Scott, P., additional, Owens, C. G., additional, Tomlin, A., additional, Smith, B., additional, Adgey, A. A. J., additional, Alvarez-Contreras, L. R., additional, Juarez, U., additional, Altamirano, A., additional, Arias, A., additional, Alvarez-San Gabriel, A., additional, Gonzalez-Pacheco, H., additional, Martinez-Sanchez, C., additional, Rahnavardi, M., additional, Keshtkar-Jahromi, M., additional, Vakili, H., additional, Gholamin, S., additional, Razavi, S. M., additional, Gilis-Januszewski, T., additional, Mellwig, K.- P., additional, Wiemer, M., additional, Gilis-Januszewski, J., additional, Peterschroeder, A., additional, Koerfer, J., additional, Horstkotte, D., additional, Vrsalovic, M., additional, Getaldic, B., additional, Vrkic, N., additional, Pintaric, H., additional, Khan, S., additional, Wasan, B., additional, Moretti, L., additional, Grossi, P., additional, Silenzi, S., additional, Testa, M., additional, Candelori, L., additional, Clementi, L. N., additional, Forlini, M., additional, Lando, L., additional, Pezzuoli, M. L., additional, Corradetti, P., additional, Leurent, G., additional, Pennec, P. Y., additional, Filippi, E., additional, Moquet, B., additional, Hacot, J. P., additional, Druelles, P., additional, Rialan, A., additional, Rouault, G., additional, Coudert, I., additional, Le Breton, H., additional, Gevaert, S., additional, Tromp, F., additional, Vandecasteele, E., additional, De Somer, F., additional, Van Belleghem, Y., additional, Bouchez, S., additional, Martens, F., additional, Herck, I., additional, De Pauw, M., additional, Ludka, O., additional, Sepsi, M., additional, Miklik, R., additional, Dusek, L., additional, Tomcikova, D., additional, Garcia-Acuna, J. M., additional, Aguiar-Souto, P., additional, Raposeiras Roubin, S., additional, Agra-Bermejo, R., additional, Jacquet, M., additional, Abu-Assi, E., additional, Gonzalez-Juanatey, J. R., additional, Ibatov, A., additional, Labrova, R., additional, Karlik, R., additional, Lokaj, P., additional, She, Q., additional, Deng, S. B., additional, Huang, S. H., additional, Gu, L. J., additional, Rong, J. I. A. N., additional, Wu, Z. K., additional, Li, Y., additional, Zhang, J., additional, Parascan, L., additional, Campanile, A., additional, Spinelli, L., additional, Santulli, G., additional, Ciccarelli, M., additional, De Gennaro, S., additional, Assante Di Panzillo, E., additional, Trimarco, B., additional, Iaccarino, G., additional, Bobescu, E., additional, Datcu, G., additional, Dobreanu, D., additional, Doka, B., additional, Charniot, J.- C., additional, Cosson, C., additional, Albertini, J. P., additional, Bittar, R., additional, Giral, P., additional, Cherfils, C., additional, Guillerm, E., additional, Bonnefont-Rousselot, D., additional, Rusali, A., additional, Cojocaru, L., additional, Parepa, I., additional, Koizumi, T., additional, Iida, S., additional, Sato, J., additional, Kikutani, T., additional, Muramatsu, T., additional, Nishimura, S., additional, Komiyama, N., additional, Lee, W. P., additional, Ong, B. B., additional, Haralambos, K., additional, Townsend, D., additional, Rees, J. A. E., additional, Williams, E. J., additional, Halcox, J. P., additional, Mcdowell, I., additional, Damjanovic, M., additional, Koracevic, G., additional, Djordjevic-Radojkovic, D., additional, Pavlovic, M., additional, Krstic, N., additional, Ciric-Zdravkovic, S., additional, Stojkovic, A., additional, Perisic, Z., additional, Apostolovic, S., additional, Faustino, A., additional, Seca, L., additional, Barra, S., additional, Caetano, F., additional, Providencia, R., additional, Silva, J., additional, Gomes, P., additional, Costa, G., additional, Costa, M., additional, Leitao-Marques, A., additional, Volkova, A. L., additional, Arutyunov, G. P., additional, Bylova, N. A., additional, Dayter, I. I., additional, Jao, Y. T. F. N., additional, Fang, C. C., additional, Chen, Y., additional, Yu, C. L., additional, Wang, S. P., additional, Valencia, J., additional, Perez-Berbel, P., additional, Ruiz-Nodar, J. M., additional, Pineda, J., additional, Bordes, P., additional, Quintanilla, M., additional, Mainar, V., additional, Sogorb, F., additional, Santos, N., additional, Serrao, M., additional, Cafe, H., additional, Silva, B., additional, Oliveira, R., additional, Caires, G., additional, Drumond, A., additional, Araujo, J., additional, Providencia, R. A., additional, Gomes, P. L., additional, Pais, J. R., additional, Mota, P., additional, Leitao-Marques, A. M., additional, Farhan, S., additional, Jarai, R., additional, Tentzeris, I., additional, Vogel, B., additional, Freynhofer, M. K., additional, Wojta, J., additional, Huber, K., additional, Poli, M., additional, Trambaiolo, P., additional, Corsi, F., additional, De Luca, M., additional, Mustilli, M., additional, Lukic, V., additional, Simonetti, M., additional, Ferraiuolo, G., additional, Lettino, M., additional, Casella, G., additional, Conte, M. R., additional, De Luca, L., additional, Geraci, G., additional, Ceravolo, R., additional, Pani, A., additional, Fradella, G., additional, Schratter, A., additional, Thiele, H., additional, Klemm, T., additional, Demmin, K., additional, Lehmann, D., additional, Mende, M., additional, Schuler, G., additional, Pittl, U., additional, Chernova, A., additional, Nikulina, S. U., additional, Naruke, T., additional, Inomata, T., additional, Yanagisawa, T., additional, Maekawa, E., additional, Mizutani, T., additional, Shinagawa, H., additional, Nishii, M., additional, Takeuchi, I., additional, Takehana, H., additional, Izumi, T., additional, Paulo, C., additional, Mascarenhas, J., additional, Patacho, M., additional, Pimenta, J., additional, Bettencourt, P., additional, Nardai, S., additional, Szabo, G. Y., additional, Berta, B., additional, Edes, I., additional, Merkely, B., additional, Delgado Silva, J., additional, Baptista, R., additional, Faria, R., additional, Trigo, J., additional, Gago, P., additional, Gheorghe, G., additional, Nanea, I. T., additional, Cristea, A., additional, Almarichi, S., additional, Martins, H., additional, Saraiva, F., additional, Jorge, E., additional, Mendes, P. L., additional, Monteiro, P., additional, Costa, S., additional, Franco, F., additional, Providencia, L. A., additional, Nanea, T., additional, Gheorghe, G. S., additional, Visan, S., additional, Paun, N., additional, Gaber, R., additional, Delewi, R., additional, Nijveldt, R., additional, De Bruin, H. A., additional, Hirsch, A., additional, Van Der Laan, A., additional, Bouma, B. J., additional, Tijssen, J. P. G., additional, Van Rossum, A. C., additional, Zijlstra, F., additional, Piek, J. J., additional, Rus, H., additional, Donea, M., additional, Ciurea, C., additional, Ifteni, G., additional, Casolo, G., additional, Chioccioli, M., additional, Magnacca, M., additional, Del Meglio, J., additional, Comella, A., additional, Baratto, M., additional, Lera, J., additional, Salvadori, L., additional, Tessa, C., additional, Vignali, C., additional, Keca, Z., additional, Momcilov Popin, T., additional, Panic, G., additional, White, R., additional, Mateen, F., additional, Weaver, A., additional, Agmon, Y., additional, Okisheva, E., additional, Tsaregorodtsev, D., additional, Sulimov, V., additional, Amat Santos, I. J., additional, Hernandez, C., additional, Tapia, C., additional, Campo, A., additional, Fredman, D., additional, Svensson, L., additional, Rosenqvist, M., additional, Tadel-Kocjancic, S., additional, Radsel, P., additional, Knafelj, R., additional, Gorjup, V., additional, Noc, M., additional, Zima, E., additional, Jenei, Z. S., additional, Kovacs, E., additional, Osztheimer, I., additional, Molnar, L., additional, Horvath, A., additional, Becker, D., additional, Geller, L., additional, Maggi, R., additional, Furukawa, T., additional, Viscardi, V., additional, Brignole, M., additional, Leal, S. R. N., additional, Dores, H., additional, Rosario, I., additional, Monge, J., additional, Carvalho, M. J., additional, Arroja, I., additional, Leitao, A., additional, Fonseca, C., additional, Aleixo, A., additional, Silva, A., additional, Keuleers, S., additional, Herijgers, P., additional, Herregods, M. C., additional, Budts, W., additional, Dubois, C., additional, Meuris, B., additional, Verhamme, P., additional, Flameng, W., additional, Van De Werf, F., additional, Adriaenssens, T., additional, Badran, H., additional, Elnoamany, M., additional, Lolah, T., additional, Olariu, C., additional, Macarie, C., additional, Mollik, M. A. H., additional, Hassan, A. I., additional, Paul, T. K., additional, Haque, M. Z., additional, Jahan, R., additional, Rahmatullah, M., additional, Khatun, M. A., additional, Rahman, M. T., additional, Chowdhury, M. H., additional, Bustamante Munguira, J., additional, Tamayo, E., additional, Garcia-Cuenca, I., additional, Bustamante, E., additional, Gualis, J., additional, Gomez-Martinez, M. L., additional, Florez, S., additional, Gomez-Herreras, J. I., additional, Ramirez Rodriguez, R., additional, Ramirez Rodriguez, A. M., additional, Garcia-Bello, M. A., additional, Hernadez Ortega, E., additional, Caballero Dorta, E., additional, Garcia Quintana, A., additional, Piro Mastraccio, V., additional, Medina Fernandez Aceytuno, A., additional, Assanelli, E., additional, De Metrio, M., additional, Rubino, M., additional, Lauri, G., additional, Cabiati, A., additional, Campodonico, J., additional, Grazi, M., additional, Moltrasio, M., additional, Marana, I., additional, Marenzi, G., additional, Lovlien, M., additional, Schei, B., additional, Picon-Heras, R., additional, Acebal, C., additional, Garcia Rubira, J. C., additional, Vivas Balcones, D., additional, Nunez-Gil, I., additional, Ruiz-Mateos, B., additional, Ibanez, B., additional, Fernandez-Ortiz, A., additional, Vintila, V. D., additional, Enescu, O. A., additional, Stoicescu, C. I., additional, Udroiu, C., additional, Cinteza, M., additional, Tatu - Chitoiu, G., additional, Vinereanu, D., additional, Fresco, C., additional, De Biasio, M., additional, Muser, D., additional, Sappa, R., additional, Morocutti, G., additional, Bernardi, G., additional, Proclemer, A., additional, Fontanella, B., additional, Affatato, A., additional, Ciccarese, C., additional, Sacchini, M., additional, Volpini, M., additional, Bianchetti, F., additional, Verzura, G., additional, Dei Cas, L., additional, Pudil, R., additional, Blaha, V., additional, Vojacek, J., additional, Paraskevaidis, I., additional, Ikonomidis, I., additional, Parissis, J., additional, Papadopoulos, C., additional, Stasinos, V., additional, Bistola, V., additional, Anastasiou-Nana, M., additional, Shochat, M., additional, Shotan, A., additional, Kazatsker, M., additional, Gurovich, V., additional, Asif, A., additional, Noiman, E., additional, Levy, Y., additional, Blondhaim, D., additional, Rabinovich, P., additional, Meisel, S., additional, Petrovic, S., additional, Glasnovic, J., additional, Tomasevic, M., additional, Sakac, D., additional, Obradovic, S., additional, Londono Sanchez, O., additional, Pacreu, S., additional, Torres, L., additional, Mihaylov, G., additional, Shaban, G. M., additional, Trendafilova, E., additional, Krasteva, V., additional, Mudrov, T. S., additional, Didon, J. P., additional, Panageas, V., additional, Vlachos, N., additional, Pernat, A., additional, Radan, I., additional, Mozina, H., additional, Pepi, P., additional, Cionini, F., additional, Baccaglioni, N., additional, Viertel, A., additional, Havers, J., additional, Ballard, G., additional, Groenefeld, G., additional, Branco, L. M., additional, Ferreira, L., additional, Fiarresga, A., additional, Lettieri, L., additional, Reggiani, A., additional, Juarez Prera, R., additional, Blanco Palacios, G., additional, Martin, A.- C., additional, Manzo Silberman, S., additional, Chaib, A., additional, Varenne, O., additional, Allouch, P., additional, Salengro, E., additional, Jegou, A., additional, Margot, O., additional, Spaulding, C., additional, Diego, A., additional, De Miguel, A., additional, Cuellas, C., additional, Fraile, E., additional, Martin, J., additional, Vega, B., additional, Bangueses, R., additional, Fernandez-Vazquez, F., additional, Perez De Prado, A., additional, Leal, S., additional, Correia, M. J., additional, Monge, J. C., additional, Abecasis, J., additional, Garcia-Garcia, C., additional, Subirana, I., additional, Sala, J., additional, Bruguera, J., additional, Valle, V., additional, Sanz, G., additional, Fiol, M., additional, Aros, F., additional, Marrugat, J., additional, Elosua, R., additional, Barra, S. N. C., additional, Leitao Marques, A., additional, Yang, Y. J., additional, Xu, B., additional, Song, G. Y., additional, G, R. L., additional, Aleksic, A., additional, Serpytis, P., additional, Rucinskas, K., additional, Kalinauskas, A., additional, Karvelyte, N., additional, Santos De Sousa, C. I., additional, Ferreira, S., additional, Calaca, J., additional, Lousada, N., additional, Palma Reis, R., additional, Gualandro, D. M., additional, Seguro, L. F. B. C., additional, Braga, F. G. M., additional, Silvestre, O. M., additional, Lage, R. L., additional, Fabri, J., additional, Oliveira, M. T., additional, Urbano Moral, J. A., additional, Torres Llergo, J., additional, Solanilla Rodriguez, R., additional, Sanchez Gonzalez, A., additional, Martinez Martinez, A., additional, Den Uil, C. A., additional, Lagrand, W. K., additional, Van Der Ent, M., additional, Jewbali, L. S. D., additional, Cheng, J. M., additional, Spronk, P. E., additional, Simoons, M. L., additional, Mornos, C., additional, Dragulescu, D., additional, Ionac, A., additional, Guardado, J., additional, Azevedo, O., additional, Fernandes, M., additional, Canario-Almeida, F., additional, Sanfins, V., additional, Pereira, A., additional, Almeida, J., additional, Kaplunova, V. U., additional, Belenkov, Y. N., additional, Privalova, E. V., additional, Fomin, A. A., additional, Suvorov, A. Y., additional, Goodkova, A., additional, Rubakova, M. G., additional, Kuznetsova, I. A., additional, Semernin, E. N., additional, Keshavarzi, F., additional, Kojuri, J., additional, Mikhailov, V. M., additional, Vezhenkova, I. V., additional, Goodkova, A. Y. A., additional, Pavlovic, I., additional, Schwarz, M., additional, Jakl, G., additional, Smetana, P., additional, Perkmann, T., additional, Mayr, A., additional, Mair, J., additional, Klug, G., additional, Schocke, M., additional, Trieb, T., additional, Jaschke, W., additional, Pachinger, O., additional, Metzler, B., additional, Bronze Carvalho, L., additional, Azevedo, J., additional, Andrade, M. L., additional, Relvas, M. J., additional, Coucello, J., additional, Morais, G., additional, Seabra, M., additional, Afamefule, F., additional, Luaces Mendez, M., additional, Teijeiro-Mestre, R., additional, Nunez-Gil, I. J., additional, Leco-Gil, N., additional, Madronal-Cerezo, E., additional, Zannin, I., additional, Ruiz, J., additional, Orynchak, M. A., additional, Vakalyuk, I. I., additional, Vakalyuk, I. P., additional, Berezin, A., additional, Panasenko, T., additional, Cavusoglu, Y., additional, Cavusoglu, A., additional, Unluoglu, I., additional, Tek, M., additional, Demirustu, C., additional, Gorenek, B., additional, Unalacak, M., additional, Birdane, A., additional, Yuksel, F., additional, Ata, N., additional, Halcox, J. P. J., additional, Beyaztas, A., additional, Entok, E., additional, Uslu, I., additional, Schaefer, A., additional, Flierl, U., additional, Seydelmann, N., additional, Bauersachs, J., additional, Calmac, L., additional, Marinescu, S., additional, Tatu Chitoiu, G., additional, Fruntelata, A. G., additional, Hamdi, S., additional, Maazoun, Y., additional, Neji, A., additional, Farhat, O., additional, Majdoub, M., additional, Ben Hamda, K., additional, Maatouk, F., additional, Balanescu, S. M., additional, Nedelciuc, I., additional, Deleanu, D., additional, Ortan, F., additional, Mot, S., additional, Sinnaeve, P. R., additional, Moreels, S., additional, Coosemans, M., additional, Vydt, T., additional, Desmet, W., additional, Tobing, D., additional, Rifnaldi, R., additional, Juzar, D., additional, Firdaus, I., additional, Dharma, S., additional, Irmalita, I., additional, Kalim, H., additional, Bejiqi, R., additional, Retkoceri, R., additional, Bejiqi, H., additional, Kryeziu, L., additional, Kelmendi, M., additional, Borovci, S. H., additional, Victor, S. M., additional, Gnanaraj, A., additional, Deshmukh, R., additional, Mullasari, A. S., additional, Yahalom, M., additional, Kaiyal, R. S., additional, Roguin, N., additional, Bornstein, J., additional, Atar, S., additional, Farah, R., additional, Seca, L. F., additional, Leitao Marques, A. M., additional, Margato, R., additional, Sousa, P., additional, Ribeiro, H., additional, Rocha, L., additional, Correia, A., additional, Moreira, J. I., additional, Carvalho, H. C., additional, Afifi, M., additional, Abed, N., additional, Suarez-Barrientos, A., additional, Vivas, D., additional, Castro-Ferreira, F., additional, Franco, E., additional, Garcia-Rubira, J. C., additional, Fuster, V., additional, Macaya, C., additional, Ibanez Cabeza, B., additional, Salinger, S., additional, Milic, D., additional, Stanojlovic, T., additional, Kostic, T., additional, Khan, M. A., additional, Vrapi, F., additional, Naeem, K., additional, Davar, J., additional, Hristova, K., additional, Pencheva, G., additional, Radeva, R., additional, Milanov, S., additional, Fareed, A., additional, Oraby, M., additional, Nasr, G. M., additional, Maklady, F., additional, Dupouy, P., additional, Sorensen, J. T., additional, Terkelsen, C. J., additional, Lassen, J. F., additional, Trautner, S., additional, Christensen, E. F., additional, Nielsen, T. T., additional, Botker, H. E., additional, Andersen, H. R., additional, Thygesen, K. A., additional, Checco, L., additional, Usmiani, T., additional, Sbarra, P. L., additional, Boffini, M., additional, Saviolo, R., additional, Grasso, C., additional, Conrotto, F., additional, Marchetti, M., additional, Rinaldi, M., additional, Marra, S., additional, Moscoso Costa, F., additional, Ferreira, J., additional, Raposo, L., additional, Aguiar, C., additional, Trabulo, M., additional, Silva, J. A., additional, Marques, V., additional, Swiatkowski, A., additional, Kowalczyk, J., additional, Lenarczyk, R., additional, Chodor, P., additional, Honisz, G., additional, Was, T., additional, Swierad, M., additional, Sredniawa, B., additional, Polonski, L., additional, Kalarus, Z., additional, Postadzhiyan, A. S., additional, Velinov, H., additional, Velchev, V., additional, Hazarbasanov, D., additional, Apostolova, M., additional, Finkov, B., additional, Petrovic, M., additional, Jovelic, A., additional, Canji, T., additional, Srdanovic, I., additional, Popov, T., additional, Golubovic, M., additional, Pavlovic, K., additional, Cemerlic-Adjic, N., additional, Bro-Jeppesen, J., additional, Kjaergaard, J., additional, Wanscher, M. C., additional, Nielsen, S. L., additional, Rasmussen, L. S., additional, Hassager, C., additional, Khan, M., additional, Crolla, E., additional, Morley, H., additional, Akeroyd, L., additional, Beaini, Y., additional, Morley, C., additional, Bekeredjian, R. H., additional, Krumsdorf, U., additional, Rottbauer, W., additional, Katus, H. A., additional, Pleger, S., additional, Botelho, A., additional, Quintal, N., additional, Faria, P., additional, Gomes, S., additional, Roussel, J. C., additional, Senage, T., additional, Perigaud, C., additional, Habash, O., additional, Michel, M., additional, Treilhaud, M., additional, Despins, P., additional, Trochu, J. N., additional, Baron, O., additional, Duveau, D., additional, Kitsiou, A. N., additional, Giannakopoulos, K., additional, Papadimitriou, G., additional, Karas, S., additional, Babic, Z., additional, Nikolic Heitzler, V., additional, Milicic, D., additional, Bergovec, M., additional, Raguz, M., additional, Mirat, J., additional, Strozzi, M., additional, Plazonic, Z., additional, Giunio, L., additional, Steiner, R., additional, Freynhofer, M., additional, Brozovic, I., additional, Bruno, V., additional, Leherbauer, L., additional, Djurkovic, M., additional, Willheim, M., additional, Huebl, W., additional, Hahne, S., additional, Kozanli, I., additional, Kalla, K., additional, Geppert, A., additional, Unger, G., additional, Simoes Marques Assuncao Caetano, A. F., additional, Faustino, C., additional, Ariza Sole, A., additional, Sanchez Salado, J. C., additional, Lorente Tordera, V., additional, Martinez Garcia, V., additional, Salazar Mendiguchia Y Garcia, J., additional, Gomez Hospital, J. A., additional, Maristany Daunert, J., additional, Berdejo Gago, F. J., additional, Esplugas Oliveras, E., additional, Brzozowska-Czarnek, A., additional, Urbanik, A., additional, Kakouros, N., additional, Kakouros, S., additional, Lekakis, J., additional, Rizos, J., additional, Kokkinos, D., additional, Venevtseva, J., additional, Melnikov, A., additional, Valiahmetov, M., additional, Gomova, T., additional, Perelomova, I., additional, Ferrer Hita, J. J., additional, Bosa-Ojeda, F., additional, Sanchez-Grande-Flecha, A., additional, Yanes-Bowden, G., additional, Vargas-Torres, M. J., additional, Rodriguez-Gonzalez, A., additional, Rubio-Iglesias-Garcia, C., additional, Dominguez-Rodriguez, A., additional, Enjuanes-Grau, C., additional, Marrero-Rodriguez, F., additional, Suceveanu, A. I., additional, Suceveanu, A., additional, Mazilu, L., additional, Alexandrescu, L., additional, Dumitru, E., additional, Miu, V., additional, Jitari, V., additional, Voinea, F. L., additional, Balachandran, K. P., additional, Schofield, R., additional, Sankaranarayanan, R., additional, Helm, K., additional, Crowe, C., additional, Singh, R., additional, Mcdonald, J., additional, Chuen, M. J., additional, Kobusiak-Prokopowicz, M., additional, Preglowska, M., additional, Mysiak, A., additional, Doi, T., additional, Sakoda, T., additional, Akagami, T., additional, Naka, T., additional, Tsujino, T., additional, Masuyama, T., additional, Ohyanagi, M., additional, Kume, N., additional, Mitsuoka, H., additional, Hayashida, K., additional, Tanaka, M., additional, Biasucci, L. M., additional, Della Bona, R., additional, Biasillo, G., additional, Leo, M., additional, Zaninotto, M., additional, Plebani, M., additional, Crea, F., additional, Dellabona, R., additional, Gok, B., additional, Unalir, A., additional, Timuralp, B., additional, Nikulina, N., additional, Yakushin, S. S., additional, Furmenko, G. I., additional, Akinina, S. A., additional, Ingrid, R., additional, Bronze, L., additional, Djambazov, S., additional, Zhivkov, A., additional, Maznev, I., additional, Ingeliev, M., additional, Slavov, R., additional, Cvetkova, N., additional, Patarinski, V., additional, Groch, L., additional, Horak, J., additional, Dimitrov, N., additional, Hayrapetyan, H. G., additional, Cabanas-Grandio, P., additional, Pena-Gil, C., additional, Mc Keag, N. A., additional, Mc Cann, C. J., additional, Cardwell, C., additional, Young, I. S., additional, Mikhalchikova, N., additional, Burova, N., additional, Zaccaria, M., additional, Palmisano, P., additional, Palumbo, V., additional, Ciccone, M. M., additional, Favale, S., additional, Chen, K. C., additional, Yin, W. H., additional, Liu, J. H., additional, Goncalves, S., additional, Santos, J. F., additional, Amador, P., additional, Soares, L. N., additional, Zahidova, K., additional, Guliyev, F., additional, Zahidov, N., additional, Carrilho-Ferreira, P., additional, Marques, J. S., additional, Carvalho De Sousa, J., additional, Uthoff, H., additional, Thalhammer, C., additional, Potocki, M., additional, Reichlin, T., additional, Noveanu, M., additional, Aschwanden, M., additional, Staub, D., additional, Arenja, N., additional, Socrates, T., additional, Mueller, C., additional, Zhao, Y., additional, Wu, X., additional, Xue, Q., additional, Gao, L., additional, Lin, H., additional, Wang, S., additional, Watanabe, K., additional, Kawamura, A., additional, Seko, T., additional, Omura, A., additional, Sakabe, S., additional, Kasai, A., additional, Starodubova, A. V., additional, Storozhakov, G., additional, Kisliak, O., additional, Hautieva, F., additional, Tursheva, M., additional, Fedotova, N., additional, Di Maio, R. C., additional, Mclaughlin, J., additional, Allen, J. D., additional, Anderson, J. M. C., additional, Khaled Nagi, H., additional, Tayeh, O., additional, Farok, W., additional, Mousa, A., additional, Neuzil, P., additional, Skoda, J., additional, Petru, J., additional, Sediva, L., additional, Kralovec, S., additional, Holy, F., additional, Holdova, K., additional, Jehlicka, P., additional, Plasil, P., additional, Reddy, V. Y., additional, Alabakovska, S., additional, Labudovic, D., additional, Jovanova, S., additional, Tosheska, K., additional, Alabakovski, M., additional, Jeevaratnam, K., additional, Tee, S. P., additional, Zhang, Y., additional, Guzadhur, L., additional, Gurung, I. S., additional, Duehmke, R., additional, Grace, A. A., additional, Lei, M., additional, Huang, C. L., additional, Ishibashi, Y., additional, Yamauchi, M., additional, Akashi, Y., additional, Musha, H., additional, Miyake, F., additional, Hnatek, T., additional, Kamenik, L., additional, Sedlon, P., additional, Luxova, J., additional, Steuerova, B., additional, Skvaril, J., additional, Cernohous, M., additional, Zavoral, M., additional, Ratkovic, N., additional, Nemanja Djenic, N. R., additional, Aleksandra Jovelic, A. J., additional, Slobodan Obradovic, S. O., additional, Branko Gligic, B. G., additional, Kletsiou, E., additional, Giannakopoulou, M., additional, Bozas, E., additional, Iliodromitis, E. K., additional, Papathanassoglou, E. D. E., additional, Anton, M., additional, Anton, G., additional, Muraru, M., additional, Salinger Martinovic, S., additional, Radosavljevic, M., additional, Stanojevic, D., additional, Zivkovic, M., additional, Pessoa, T., additional, Aspromonte, N., additional, Ronco, C., additional, Tubaro, M., additional, Santini, M., additional, Colivicchi, F., additional, Aiello, A., additional, Cruz, D., additional, Anzoletti Boscolo, A., additional, Vianello, G., additional, Valle, R., additional, Parspour, A., additional, Watkins, S., additional, Datta, D., additional, Nikishin, A. G., additional, Pirnazarov, M. M., additional, Nurbaev, T. A., additional, Motovska, Z., additional, Fischerova, M., additional, Osmancik, P., additional, Maly, M., additional, Widimsky, P., additional, Pavli, E., additional, Dibra, A., additional, Mehilli, J., additional, Dibra, L., additional, Schoemig, A., additional, Kastrati, A., additional, Carmo, P., additional, Almeida, M., additional, Teles, R., additional, Goncalves, P., additional, Brito, J., additional, D'ascenzo, F., additional, Gonella, A., additional, Longo, G., additional, Pullara, A., additional, Moretti, C., additional, Sciuto, F., additional, Omede', P., additional, Biondi Zoccai, G., additional, Trevi, G. P., additional, Sheiban, I., additional, Cafe, H. M., additional, Pereira, D., additional, Freitas, D., additional, Ortiz Berbel, D., additional, Rabasa Baraibar, J. M., additional, Leone, A. M., additional, De Caterina, A., additional, Aurelio, A., additional, Sciahbasi, A., additional, Lioy, E., additional, Trani, C., additional, Burzotta, F., additional, Porto, I., additional, Rebuzzi, A. G., additional, Trusinskis, K., additional, Juhnevica, D., additional, Strenge, K., additional, Sondore, D., additional, Kumsars, I., additional, Jegere, S., additional, Narbute, I., additional, Grave, A., additional, Zakke, I., additional, Erglis, A., additional, Ferrari, C., additional, Bartorelli, A. L., additional, Saeed, M., additional, Cozma, D., additional, Pescariu, S., additional, Dragulescu, S. I., additional, Kamal, H. S., additional, Abdelfattah, A., additional, Abdelbary, A. M., additional, Elassar, H., additional, Naggar, A., additional, Khaled, M., additional, Fareed, A. M., additional, Pernes, J. M., additional, Gaux, J. C., additional, Prull, M. W., additional, Sasko, B., additional, Wirdemann, H., additional, Bittlinsky, A., additional, Butz, T., additional, Trappe, H. J., additional, Perazzolo Marra, M., additional, Cacciavillani, L., additional, Marzari, A., additional, De Lazzari, M., additional, Turri, R., additional, China, P., additional, Corbetti, F., additional, Iliceto, S., additional, Stazhadze, L. L., additional, Spiridonova, E. A., additional, Bulanova, N. A., additional, Ermolaev, A. A., additional, Savic, L., additional, Mrdovic, I., additional, Krljanac, G., additional, Perunicic, J., additional, Asanin, M., additional, Lasica, R., additional, Matic, M., additional, Vasiljevic, Z., additional, Ostojic, M., additional, Tichy, M., additional, Andrys, C., additional, Conti, A., additional, Poggioni, C., additional, Viviani, G., additional, Bulletti, F., additional, Boni, V., additional, Luzzi, M., additional, Vicidomini, S., additional, Donati, M., additional, Del Taglia, B., additional, Pini, R., additional, Sousa, O., additional, Fontes-Carvalho, R., additional, Caeiro, D., additional, Dias Ferreira, N., additional, Silva, G., additional, Pereira, E., additional, Ribeiro, J., additional, Albuquerque, A., additional, Gama Ribeiro, V., additional, Murai, M., additional, Takeda, Y., additional, Shinmyo, T., additional, Tanigawa, J., additional, Hazui, H., additional, Nakakohji, T., additional, Ohishi, Y., additional, Hoshiga, M., additional, Ishihara, T., additional, Hanafusa, T., additional, Belohlavek, J., additional, Rohn, V., additional, Kunstyr, J., additional, Lips, M., additional, Semrad, M., additional, Mlejnsky, F., additional, Tosovsky, J., additional, Linhart, A., additional, Lindner, J., additional, Sablik, Z., additional, Samborska-Sablik, A., additional, Drozdz, J., additional, Gaszynski, W., additional, Izquierdo-Gomez, M. M., additional, Juarez-Prera, R., additional, Blanco-Palacios, G., additional, Lakhdar, R., additional, Drissa, M., additional, Jedaida, B., additional, Drissa, H., additional, Sampaio, F., additional, Hsin, H.- T., additional, Huang, J.- H., additional, Chiu, K.- M., additional, Chen, Z.- S., additional, Lin, P.- C., additional, Chen, L.- Y., additional, Chu, S.- H., additional, Efthimiadis, I., additional, Skendros, P., additional, Sarantopoulos, A., additional, Boura, P., additional, Van Der Laan, A. M., additional, Van Der Vleuten, P. A., additional, Klees, M., additional, Tijssen, J. G. P., additional, Backus, B. E., additional, Six, A. J., additional, Kelder, J. H., additional, Mosterd, A., additional, Mast, E. G., additional, Mast, T. P., additional, Braam, R., additional, Tio, R., additional, Veldkamp, R., additional, Doevendans, P. A., additional, Paarup Dridi, N., additional, Holmvang, L., additional, Engstroem, T., additional, Rekik, S., additional, Brunet, J., additional, Hager, F. X., additional, Bayet, G., additional, Meille, L., additional, Quatre, J. M., additional, Sainsous, J., additional, Chu, P.- H., additional, Tang, C.- H., additional, Pogosova, N., additional, Koltunov, I. E., additional, Sapunova, I. D., additional, Vigodin, V. A., additional, Uhliar, R., additional, Schmidt, A., additional, Brockmeyer, B., additional, Suzuki, A., additional, Eki, Y., additional, Higuchi, H., additional, Yukawa, A., additional, Yamauchi, R., additional, Sato, Y., additional, Endo, Y., additional, Salazar Mendigucha Garcia, J., additional, Homs Vila, S., additional, Cequier Fillat, A., additional, Andion Ogando, R., additional, Sandin Fuentes, M., additional, Vegas Valle, J. M., additional, Gonzalez Garcia, I. A., additional, Duro Aguado, I. A., additional, Palomino Doza, A. J., additional, Gomez Salvador, I., additional, San Roman Calvar, J. A., additional, Mamarasulov, T. M., additional, Todorovic, L., additional, Cherneva, Z. C. H., additional, Denchev, S. D., additional, Heltai, K., additional, Boytsov, A., additional, Nikulina, N. N., additional, Zanna, D., additional, Marangelli, V., additional, Caiati, C., additional, Picon Heras, R., additional, Loureiro, M. J., additional, Urazovskaya, I., additional, Vinogradova, D., additional, Vasilieva, E., additional, Shpektor, A., additional, Conti, E., additional, Musumeci, M. B., additional, Lauri, F. M., additional, Dito, E., additional, De Giusti, M., additional, Lallo, A., additional, Fusco, D., additional, Davoli, M., additional, Volpe, M., additional, Autore, C., additional, Gamra, H., additional, Dridi, Z., additional, Hassine, M., additional, Addad, F., additional, Gherissi, I., additional, Reda, A., additional, Mahjoub, M., additional, Bouraoui, S., additional, Abdennadher, M., additional, Betbout, F., additional, Mota, P. M. F. P., additional, Silva, J. D., additional, Jankovic Tomasevic, R., additional, Djordjevic, V., additional, Djordjevic Radojkovic, D., additional, Scafa Udriste, A., additional, Fruntelata, A., additional, Gainoiu, E., additional, Bogdan, S., additional, Zamfir, D., additional, Teodorescu, C., additional, Guran, M., additional, Constantinescu, D., additional, Konopka, A., additional, Banaszewski, M., additional, Wojtkowska, I., additional, Stepinska, J., additional, Vidergold, J. V., additional, Osipova, I. V., additional, Tavrovskaya, T. V., additional, Galkina, J. V., additional, Timofeev, A. V., additional, Vorobyov, R. I., additional, Vorobyova, E. N., additional, Matos, L., additional, Carvalho, A. C. C., additional, Oliveira, W., additional, Cintra, F., additional, Poyares, D., additional, Andersen, M., additional, Martins, R., additional, Tufik, S., additional, Ostadal, P., additional, Brada, J., additional, Horakova, S., additional, Mlcek, M., additional, Hrachovina, V., additional, Kittnar, O., additional, Gorudko, I. V., additional, Buko, I. V., additional, Cherenkevich, S. N., additional, Polonetsky, L. Z., additional, Plotkin, V. Y., additional, Timoshina, M. A., additional, Azanchevskaya, S. V., additional, Chromov-Borisov, N. N., additional, Vorlat, A., additional, Snoep, L., additional, Claeys, M. J., additional, Vrints, C. J., additional, Palazzuoli, A., additional, Caputo, M., additional, Quatrini, I., additional, Calabro, A., additional, Antonelli, G., additional, Campagna, M. S., additional, Franci, B., additional, Nuti, R., additional, Maisel, A., additional, Negrini, M., additional, Minora, T., additional, Marino, P., additional, Seregni, R., additional, Tavlueva, E., additional, Barbarash, O., additional, Barbarash, L., additional, Janota, T., additional, Kudlicka, J., additional, Malik, K., additional, Wichterle, D., additional, Hradec, J., additional, Body, R., additional, Carley, S. D., additional, Mcdowell, G., additional, Nuttall, M., additional, Wibberley, C., additional, France, M., additional, Cruickshank, J. K., additional, Mackway-Jones, K., additional, Leon, M., additional, Cozma, C., additional, Mitu, F., additional, Almeida, D. R., additional, Dias, C. B., additional, Burazor, I., additional, Burazor, M., additional, Krstic, M., additional, Lazovic, M., additional, Vukmanovic, M., additional, Djordjevic, J., additional, Radovanovic, Z., additional, Ilic, D., additional, Bosnjakovic, P., additional, Ferreira, A. C., additional, Mateus, P. S., additional, Fontes, P., additional, Teixeira, T., additional, Conte, G., additional, Menozzi, A., additional, Solinas, E., additional, Bolognesi, M. G., additional, Tadonio, I., additional, Mantovani, F., additional, Cattabiani, A., additional, Vignali, L., additional, Ardissino, D., additional, Tautu, O., additional, Alexandrescu, A., additional, Niculescu, R., additional, Jankovic, R., additional, Bozinovic, N., additional, Santos, C., additional, Costa, F., additional, Cardoso, G., additional, Correia, I., additional, Fountoulaki, K., additional, Kastellanos, S., additional, Voltirakis, E., additional, Kokotos, A., additional, Michalakeas, C., additional, Kontsas, K., additional, Hasioti, K., additional, Iliodromitis, E. T., additional, Sandin Fuentes, M. G., additional, Zatarain Nicolas, E., additional, Martinez Uruena, N., additional, Alvarado Montes De Oca, M., additional, Dytrych, V., additional, Kovarnik, T., additional, Smid, O., additional, Kral, A., additional, Aroutunov, A. G., additional, Intwala, S., additional, Jegere, I., additional, Shaalan, H. S. H., additional, Pagava, Z., additional, Agladze, R., additional, Shakarishvili, R., additional, Sharashidze, N., additional, Gujejiani, L., additional, Saatashvili, G., additional, Katova, T. Z., additional, Kostova, V., additional, Simova, Y., additional, Vukotic, S., additional, Rafajlovski, S., additional, Romanovic, R., additional, Antonijevic, N., additional, Gligic, B., additional, Hutyra, M., additional, Skala, T., additional, Horak, D., additional, Vindis, D., additional, Taborsky, M., additional, Contine, A., additional, Del Pinto, M., additional, Angeli, F., additional, Verdecchia, P., additional, Borgognoni, F., additional, Grikstaite, E., additional, Pantano, P., additional, Ambrosio, G., additional, Cavallini, C., additional, Bonanad, C., additional, Sanchis, J., additional, Bodi, V., additional, Nunez, J., additional, Bosch, X., additional, Heras, M., additional, Pellicer, M., additional, Llacer, A., additional, Adao, L., additional, Oliveira, M., additional, Goncalves, H., additional, Primo, J., additional, Gama, V., additional, Lombardi, C., additional, Metra, M., additional, Bugatti, S., additional, Pasotti, E., additional, Quinzani, F., additional, Adamo, M., additional, Villa, C., additional, Rovetta, R., additional, Manerba, A., additional, Mariani, M., additional, Dushpanova, A., additional, Baroni, M., additional, Cerone, E., additional, Nardelli, A., additional, Gianetti, J., additional, Berti, S., additional, Feliciano, F., additional, Soares, R., additional, Santos, S., additional, Kruger, A., additional, Vondrakova, D., additional, Herget, J., additional, Navarro, C., additional, Cromie, N. A., additional, Adgey, J. A. A., additional, Caeiro Pereira, D., additional, Braga, P., additional, Fontes Carvalho, R., additional, Rodrigues, A., additional, Goncalves, M., additional, Simoes, L., additional, and Borisov, K. V., additional

Published
2010
Full Text
View/download PDF

8. Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent

Author

Zheng H, Barragan P, Thierry Corcos, Jb, Siméoni, Favereau X, Po, Roquebert, Guérin Y, and Sainsous J

Subjects
Adult, Aged, 80 and over, Male, Phosphorylcholine, Coronary Stenosis, Thrombosis, Middle Aged, Coronary Angiography, Blood Vessel Prosthesis, Coronary Restenosis, Blood Vessel Prosthesis Implantation, Treatment Outcome, Coated Materials, Biocompatible, Feasibility Studies, Humans, Female, Stents, Prospective Studies, Angioplasty, Balloon, Coronary, Aged
Abstract

The BiodivYsio stent is a new stent coated with phosphorylcholine, a biocompatible molecule designed to reduce the formation of thrombus and potentially the risk of restenosis. The feasibility, safety, and efficacy of elective and urgent implantation of this coated coronary stent were prospectively studied.We studied 224 patients who underwent elective (67%) or bail-out implantation of 303 BiodivYsio stents in 286 lesions. Most lesions (62%) had unfavorable characteristics (type B2 or C) and half of them (50%) had thrombus and/or chronic total occlusion. Clinical follow-up was obtained in all patients at one month and in the first 132 patients at six months. Repeat angiography was undertaken in all patients with recurrent ischemia. Successful stent deployment was achieved in 284 lesions (99.3%). One emergency coronary artery bypass graft (CABG) was required. Angiographic success rate was 98.3% (281/286). There was 1 (0.4%) subacute stent thrombosis associated with Q-wave myocardial infarction and two (0.9%) in-hospital deaths. Reference vessel diameter was 2.82 +/- 0.32 mm. Minimum luminal diameter (MLD) increased from 0.38 +/- 0.25 mm to 2.97 +/- 0.35 mm and diameter stenosis decreased from 83.8 +/- 12.1% to 5.8 +/- 9.7%. Clinical restenosis rate was 6.1% (8/132 patients) at 6-month follow-up. Target vessel revascularization rate at 6-month follow-up was 5.4%.This initial clinical experience indicates that the implantation of stents coated with phosphorylcholine appears to be safe and efficacious in the treatment of complex coronary lesions and is associated with an extremely low target vessel revascularization rate.

13. Five-year clinical outcomes using the bioresorbable vascular scaffold: Insights from the FRANCE ABSORB registry.

Author

Landolff Q, Lefèvre T, Fajadet J, Sainsous J, Lhermusier T, Elhadad S, Tarragano F, Ranc S, Ghostine S, Cayla G, Marco F, Garot P, Maillard L, Motreff P, Delarche N, De Labriolle A, Pansieri M, Morelle JF, Cazaux P, Moulichon ME, Chopat P, Angoulvant D, Bataille V, Le Breton H, and Koning R

Subjects
Male, Humans, Adult, Middle Aged, Aged, Female, Absorbable Implants, Everolimus, Treatment Outcome, Prosthesis Design, Time Factors, Registries, Anticoagulants, Drug-Eluting Stents, Diabetes Mellitus, Percutaneous Coronary Intervention adverse effects, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease surgery
Abstract

Background: Randomized trials comparing the first-generation absorb bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, CA, USA) with a drug-eluting stent showed a moderate but significant increase in the rate of 3-year major adverse cardiac events and scaffold thrombosis, followed by a decrease in adverse events after 3 years., Aim: The objective of this study was to assess the 5-year outcomes of patients treated with at least one absorb BVS and included in the FRANCE ABSORB registry., Methods: All patients treated in France with an absorb BVS were prospectively included in a large nationwide multicentre registry. The primary efficacy outcome was the occurrence of 5-year major adverse cardiac events. Secondary efficacy outcomes were the rates of 5-year target vessel revascularization and definite/probable scaffold thrombosis., Results: Between September 2014 and April 2016, 2,070 patients were included in 86 centres (mean age 55±11 years; 80% men; 49% with acute coronary syndrome). The rates of 1-, 3- and 5-year major adverse cardiac events were 3.9%, 9.4% and 12.1%, respectively (including cardiac death in 2.5% and target vessel revascularization in 10.4%). By multivariable analysis, diabetes, oral anticoagulation, the use of multiple Absorb BVSs and the use of a 2.5mm diameter absorb BVS were associated with 5-year major adverse cardiac events. The rates of 1-, 3- and 5-year definite/probable scaffold thrombosis were 1.5%, 3.1% and 3.6%, respectively. By multivariable analysis, older age, diabetes, anticoagulation at discharge and the use of a 2.5mm diameter absorb BVS were associated with 5-year scaffold thrombosis., Conclusions: Absorb BVS implantation was associated with low rates of 1-year major adverse cardiac events, which increased significantly at 3-year follow-up. There was a clear decrease in the rates of scaffold thrombosis and major adverse cardiac events after 3 years., (Copyright © 2022 Elsevier Masson SAS. All rights reserved.)

Published
2022
Full Text
View/download PDF

14. Three-year clinical outcomes with the ABSORB bioresorbable vascular scaffold in real life: Insights from the France ABSORB registry.

Author

Lhermusier T, Carrie D, Cayla G, Fajadet J, Sainsous J, Elhadad S, Tarragano F, Chevalier B, Ranc S, Curinier C, Le Breton H, and Koning R

Subjects
Absorbable Implants, Adult, Aged, Everolimus, Female, Humans, Male, Middle Aged, Prospective Studies, Prosthesis Design, Registries, Treatment Outcome, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease surgery, Drug-Eluting Stents, Percutaneous Coronary Intervention adverse effects
Abstract

Objectives: The aim of this study was to determine the 3-year outcomes of patients treated with Absorb bioresorbable vascular scaffold (BVS) implantation., Background: Randomized trials and observational registries performed in patients undergoing percutaneous coronary intervention have demonstrated higher 1-year and midterm rates of device thrombosis and adverse events with BVS compared to contemporary drug eluting stent. Data on long-term follow-up of patients treated with BVS are scarce., Methods: All patients treated with BVS were included in a large nationwide prospective multicenter registry (FRANCE ABSORB). The primary endpoint was a composite of cardiovascular death, myocardial infarction, and target lesion revascularization at 3 years. Secondary endpoints were 3-year scaffold thrombosis and target vessel revascularization (TVR)., Results: Between September 2014 and April 2016, 2070 patients were included (mean age 55 ± 11 years; 80% men). The indication was acute coronary syndrome (ACS) in 49% of patients. At 3 years, the primary endpoint occurred in 184 patients (8.9%) and 3-year mortality in 43 patients (2.1%). Scaffold thrombosis and TVR rates through 3 years were, respectively, 3 and 7.6%. In a multivariable analysis, independent predictors of primary endpoint occurrence were diabetes, oral anticoagulation, active smoking, absence of initial angiographic success and the association of a total BVS length ≥30 mm with the use of 2.5 mm diameter BVS., Conclusions: Although 3-year mortality was low in this ACS population, device-related events were significant beyond 1 year. Total BVS length and 2.5 mm BVS were associated with higher rates of MACE at long-term follow-up., (© 2020 Wiley Periodicals LLC.)

Published
2021
Full Text
View/download PDF

15. Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life: 1-year results from the FRANCE ABSORB registry.

Author

Cayla G, Koning R, Fajadet J, Sainsous J, Carrié D, Elhadad S, Tarragano F, Lefévre T, Ranc S, Ghostine S, Garot P, Marco F, Maillard L, Motreff P, and Le Breton H

Subjects
Acute Coronary Syndrome diagnostic imaging, Acute Coronary Syndrome mortality, Adult, Aged, Angina, Unstable diagnostic imaging, Angina, Unstable mortality, Angioplasty, Balloon, Coronary adverse effects, Angioplasty, Balloon, Coronary mortality, Coronary Thrombosis etiology, Female, France, Humans, Male, Middle Aged, Myocardial Infarction diagnostic imaging, Myocardial Infarction mortality, Prospective Studies, Prosthesis Design, Recurrence, Registries, Risk Factors, Time Factors, Treatment Outcome, Absorbable Implants, Acute Coronary Syndrome surgery, Angina, Unstable surgery, Angioplasty, Balloon, Coronary instrumentation, Myocardial Infarction surgery
Abstract

Background: Several randomized studies have shown that bioresorbable vascular scaffold (BVS) technology is associated with an increased risk of stent thrombosis., Aim: This study aimed to assess the rates of adverse outcomes at 1 year in patients treated with the Absorb BVS (Abbott Vascular, Santa Clara, CA, USA), using data from a large nationwide prospective multicentre registry (FRANCE ABSORB)., Methods: All patients receiving the Absorb BVS in France were included prospectively in the study. Predilatation, optimal sizing and postdilatation were recommended systematically. The primary endpoint was a composite of cardiovascular death, myocardial infarction and target lesion revascularization at 1 year. Secondary endpoints were scaffold thrombosis and target vessel revascularization at 1 year., Results: A total of 2072 patients at 86 centres were included: mean age 55±11 years; 80% men. The indication was acute coronary syndrome (ACS) in 49% of cases. Predilatation and postdilatation were done in 93% and 83% of lesions, respectively. At 1 year, the primary endpoint occurred in 3.9% of patients, the rate of scaffold thrombosis was 1.5% and the rate of target vessel revascularization was 3.3%. In a multivariable analysis, diabetes and total Absorb BVS length>30mm were independently associated with the occurrence of the primary endpoint, whereas oral anticoagulation and total Absorb BVS length>30mm were independently associated with occurrence of scaffold thrombosis., Conclusions: The Absorb BVS was implanted in a relatively young population, half of whom had ACS. Predilatation and postdilatation rates were high, and 1-year outcomes were acceptable., (Copyright © 2018 Elsevier Masson SAS. All rights reserved.)

Published
2019
Full Text
View/download PDF

16. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).

Author

Didier R, Morice MC, Barragan P, Noryani AAL, Noor HA, Majwal T, Hovasse T, Castellant P, Schneeberger M, Maillard L, Bressolette E, Wojcik J, Delarche N, Blanchard D, Jouve B, Ormezzano O, Paganelli F, Levy G, Sainsous J, Carrie D, Furber A, Berlan J, Darremont O, Le Breton H, Lyuycx-Bore A, Gommeaux A, Cassat C, Kermarrec A, Cazaux P, Druelles P, Dauphin R, Armengaud J, Dupouy P, Champagnac D, Ohlmann P, Ben Amer H, Kiss RG, Ungi I, and Gilard M

Subjects
Aged, Aspirin adverse effects, Clopidogrel, Coronary Artery Disease diagnosis, Coronary Artery Disease mortality, Coronary Thrombosis etiology, Drug Administration Schedule, Drug Therapy, Combination, Female, France, Hemorrhage chemically induced, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction etiology, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention mortality, Platelet Aggregation Inhibitors adverse effects, Proportional Hazards Models, Prospective Studies, Prosthesis Design, Risk Factors, Ticlopidine administration & dosage, Ticlopidine adverse effects, Time Factors, Treatment Outcome, Aspirin administration & dosage, Coronary Artery Disease therapy, Drug-Eluting Stents, Percutaneous Coronary Intervention instrumentation, Platelet Aggregation Inhibitors administration & dosage, Ticlopidine analogs & derivatives
Abstract

Objectives: The aim of this study was to test the hypothesis that 6-month dual antiplatelet therapy (DAPT) is noninferior to 24-month DAPT in aspirin-sensitive patients., Background: The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that rates of bleeding and thrombotic events at 1 year were much the same with 6 versus 12 months of DAPT after percutaneous coronary intervention with second-generation drug-eluting stents. In this report, 2-year follow-up is presented., Methods: In a multicenter randomized study, patients with confirmed nonresistance to aspirin undergoing drug-eluting stent implantation were allocated to 6 or 24 months of DAPT. The primary endpoint was a composite of death, myocardial infarction, urgent target vessel revascularization, stroke, and major bleeding at 12 months post-percutaneous coronary intervention. The secondary endpoints comprised the same composite endpoint at 24 months and each individual component., Results: Overall, 2,031 patients from 70 centers were screened; 926 were randomized to 6-month and 924 to 24-month DAPT. Noninferiority was demonstrated for 6- versus 12-month DAPT, with an absolute risk difference of 0.11% (95% confidence interval: -1.04% to 1.26%; p = 0.0002). At 2 years, the composite endpoint was unchanged, at 3.5% for 6 months and 3.7% for 24 months (p = 0.79), and rates of myocardial infarction (1.3% vs. 1.0%; p = 0.51), stroke (0.6% vs. 0.8%; p = 0.77), and target vessel revascularization (1.0% vs. 0.3%; p = 0.09) were likewise similar. There was a trend toward higher mortality with longer DAPT (2.2% vs. 1.2%; p = 0.11). Four patients (0.4%) in the 24-month group and none in the 6-month group had major bleeding., Conclusions: Two-year outcomes in the ITALIC trial confirmed the 1-year results and showed that patients receiving 6-month DAPT after percutaneous coronary intervention with second-generation drug-eluting stent have similar outcomes to those receiving 24-month DAPT., (Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)

Published
2017
Full Text
View/download PDF

17. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.

Author

Gilard M, Barragan P, Noryani AAL, Noor HA, Majwal T, Hovasse T, Castellant P, Schneeberger M, Maillard L, Bressolette E, Wojcik J, Delarche N, Blanchard D, Jouve B, Ormezzano O, Paganelli F, Levy G, Sainsous J, Carrie D, Furber A, Berland J, Darremont O, Le Breton H, Lyuycx-Bore A, Gommeaux A, Cassat C, Kermarrec A, Cazaux P, Druelles P, Dauphin R, Armengaud J, Dupouy P, Champagnac D, Ohlmann P, Endresen K, Benamer H, Kiss RG, Ungi I, Boschat J, and Morice MC

Subjects
Aged, Clopidogrel, Coronary Artery Disease diagnosis, Coronary Artery Disease mortality, Coronary Artery Disease physiopathology, Coronary Vessels pathology, Coronary Vessels surgery, Early Termination of Clinical Trials, Europe, Everolimus, Female, Humans, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Middle East, Platelet Aggregation Inhibitors administration & dosage, Platelet Aggregation Inhibitors adverse effects, Postoperative Complications diagnosis, Postoperative Complications prevention & control, Sirolimus analogs & derivatives, Sirolimus therapeutic use, Ticlopidine administration & dosage, Ticlopidine adverse effects, Time Factors, Treatment Outcome, Aspirin administration & dosage, Aspirin adverse effects, Coronary Artery Disease therapy, Coronary Restenosis diagnosis, Coronary Restenosis etiology, Coronary Restenosis prevention & control, Drug-Eluting Stents adverse effects, Hemorrhage etiology, Hemorrhage prevention & control, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention methods, Ticlopidine analogs & derivatives
Abstract

Background: The currently recommended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent (DES) recipients is 12 months to reduce the risk of late stent thrombosis, particularly in those with acute coronary syndrome (ACS)., Objectives: This study hypothesized that antiplatelet treatment with DAPT for 6 months may be noninferior to 24-month DAPT in aspirin-sensitive patients., Methods: A multicenter, randomized study assigned patients undergoing implantation of everolimus-eluting stents with confirmed nonresistance to aspirin to receive 6- or 24-month DAPT. The primary endpoint was a composite of death, myocardial infarction, urgent target vessel revascularization, stroke, and major bleeding at 12 months post-stenting., Results: A total of 2,031 patients were enrolled in 70 European and Middle Eastern centers. The trial was prematurely terminated due to recruitment problems, leaving 941 patients randomized to 24-month DAPT and 953 to 6-month DAPT. The 2 treatment groups had similar baseline and procedural characteristics. There was no significant difference in the primary endpoint (24-month: 1.5% vs. 6-month: 1.6%; p = 0.85). Noninferiority was demonstrated for 6- versus 24-month DAPT, with an absolute risk difference of 0.11% (95% confidence interval: -1.04% to 1.26%; p for noninferiority = 0.0002). There were no significant differences in stent thrombosis or bleeding complications. In the 792 (44%) high-risk patients with ACS, primary and secondary endpoints did not significantly differ (hazard ratio: 1.7 [95% confidence interval: 0.519 to 6.057; p = 0.361])., Conclusions: Rates of bleeding and thrombotic events were not significantly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin responders. (Is There A LIfe for DES After Discontinuation of Clopidogrel [ITALICplus]; NCT01476020)., (Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)

Published
2015
Full Text
View/download PDF

18. Percutaneous management of lower limb ischemia after the use of vascular closure devices.

Author

Rekik S, Brunet J, Bayet G, Hager FX, Meille L, Quatre JM, and Sainsous J

Subjects
Aged, Arterial Occlusive Diseases etiology, Female, Femoral Artery diagnostic imaging, Follow-Up Studies, Hemostatic Techniques adverse effects, Humans, Ischemia etiology, Lower Extremity blood supply, Male, Percutaneous Coronary Intervention instrumentation, Radiography, Angioplasty, Balloon, Arterial Occlusive Diseases therapy, Hemostatic Techniques instrumentation, Ischemia therapy, Percutaneous Coronary Intervention adverse effects, Stents
Abstract

Background: Lower extremity ischemia after the use of vascular closure devices (VCDs) after transfemoral percutaneous coronary and peripheral interventions is an infrequent though relevant clinical entity. We aimed to assess immediate and midterm outcomes of a systematic endovascular approach for the treatment of VCD-related lower limb ischemia., Methods: Between 2006 and 2008, all the patients who developed lower limb ischemia after the use of a VCD in a high volume French institution were systematically managed percutaneously and constituted the study population. Clinical characteristics, immediate, and midterm outcomes are reported., Results: Of 2944 consecutive patients undergoing VCD placement after femoral access, 18 (3 men and 15 women) had VCD-related lower limb ischemia and were all managed percutaneously. Median age was 66.5 years. Devices were Angio-Seal (St Jude Medical) in 12 cases, StarClose (Abbott Vascular Devices) in 3 cases, and Perclose (Abbott Vascular Devices) in 3 cases. Limb ischemia occurred with a median delay of 2 days after device placement. Index procedures were coronary interventions in 14 cases and peripheral in 4 cases. The occlusion site was successfully crossed in all cases. Twelve patients were treated with balloon angioplasty and 6 with stent implantation. Angiographic success was obtained in all cases. After a median 32-month follow-up, only 2 patients initially treated using percutaneous transluminal angioplasty needed reintervention consisting of a balloon angioplasty in 1 case and stent implantation in the second case. At final follow-up, all the patients were asymptomatic., Conclusions: Endovascular treatment for VCD-related limb ischemia is a feasible and effective approach resulting in excellent immediate and midterm outcomes., (Copyright © 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.)

Published
2013
Full Text
View/download PDF

19. Severe stenosis of the superior mesenteric artery causing an acute coronary syndrome successfully treated by percutaneous angioplasty.

Author

Rekik S, Brunet J, Hager FX, Bayet G, Meille L, Quatre JM, and Sainsous J

Subjects
Acute Coronary Syndrome diagnosis, Aged, 80 and over, Constriction, Pathologic complications, Coronary Angiography, Electrocardiography, Female, Humans, Acute Coronary Syndrome etiology, Acute Coronary Syndrome therapy, Angioplasty, Balloon, Coronary, Mesenteric Artery, Superior pathology
Published
2011
Full Text
View/download PDF

20. EuroSCORE is a good global predictor of long-term outcomes in high-risk but not in low-risk patients after unprotected left main angioplasty.

Author

Rekik S, Brunet J, Bayet G, Hager FX, Meille L, Quatre JM, and Sainsous J

Subjects
Aged, Aged, 80 and over, Angioplasty, Balloon, Coronary instrumentation, Angioplasty, Balloon, Coronary mortality, Chi-Square Distribution, Coronary Angiography, Coronary Stenosis diagnostic imaging, Coronary Stenosis mortality, Drug Therapy, Combination, Female, France, Hospital Mortality, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction etiology, Platelet Aggregation Inhibitors therapeutic use, Predictive Value of Tests, Proportional Hazards Models, ROC Curve, Risk Assessment, Risk Factors, Stents, Survival Rate, Time Factors, Treatment Outcome, Angioplasty, Balloon, Coronary adverse effects, Coronary Stenosis therapy
Abstract

Background: Percutaneous coronary intervention is increasingly emerging as a valuable alternative to surgery for the treatment of patients with unprotected left main coronary artery (ULMCA) disease. In this study, we aimed to assess the ability of the EuroSCORE risk stratification model to predict long-term major adverse cardiac events after unprotected left main angioplasty according to the individual level of risk., Methods: Two hundred forty-six consecutive patients who underwent ULMCA in a single high volume center over a 5-year period were included. Major adverse cardiac events were defined as a combined end point of cardiac death, nonfatal myocardial infarction, or target lesion revascularization., Results: Areas under the receiver-operating characteristic curve of EuroSCORE in the entire cohort were 0.687 (P = 0.005; 95% CI: 0.575-0.846) and 0.589 (P = 0.038; 95% CI: 0.511-0.673) respectively for cardiac death and major adverse cardiac events (MACE). One hundred twenty-four patients had a EuroSCORE value > 6 and constituted the high surgical risk (HSR) group. Actuarial 4-year survivals free from cardiac death and free from MACE were significantly lower in this group respectively at 84% versus 93% (log rank P = 0.02) and 50% versus 74% (log rank P = 0.004). EuroSCORE was the only independent predictor of long-term cardiac mortality by the Cox analysis (HR = 3.95, P = 0.027, 95% CI: 1.16-13.39). It had a good discriminatory power for predicting both cardiac death and MACE with AUC respectively at was 0.705 (P = 0.01, 95% CI: 0.55-0.86) and 0.65 (P = 0.013, 95% CI: 0.54-0.78) in the HSR cohort but not in the lower risk (EuroSCORE ≤ 6) cohort., Conclusion: EuroSCORE is a good predictor not only of cardiac death but also of MACE after ULMCA angioplasty; however, the discriminatory ability of EuroSCORE appears to be limited to patients with high surgical risk as defined by EuroSCORE values > 6., (Copyright © 2010 Wiley-Liss, Inc.)

Published
2011
Full Text
View/download PDF

21. Unprotected left main angioplasty in nonagenarians: clinical characteristics, procedural features and outcome: a case series study.

Author

Rekik S, Brunet J, Bayet G, Hager FX, Meille L, Quatre JM, and Sainsous J

Subjects
Coronary Angiography, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease epidemiology, Coronary Restenosis epidemiology, Drug-Eluting Stents, Female, Humans, Male, Metals, Risk Factors, Treatment Outcome, Aged, 80 and over statistics & numerical data, Angioplasty, Balloon, Coronary statistics & numerical data, Coronary Artery Disease therapy, Stents
Abstract

Unlabelled: Limited information is available on clinical characteristics and outcomes in very old patients with unprotected left main coronary artery disease (ULMCA) undergoing percutaneous coronary intervention (PCI)., Methods: From January 2004 and December 2008, 248 patients with ULMCA stenosis underwent coronary revascularization with stent implantation. Among those, 6 were older than 90 years at the time of the procedure and were included in this study., Results: There were 5 males and 1 female; mean age was 91.5 years (range 91-93). All the patients presented with acute coronary syndromes. All of them had multivessel disease with a distal left main stenosis in 4 patients. All were deemed inoperable, with a mean EuroSCORE of 12.66 (range 10-20) and a predicted mortality at 34% (range15.8-86.6%). 5 patients received bare-metal stents and 1 patient a paclitaxel-eluting stent. Rotational atherectomy was required in 2 patients. Provisional side branch T-stenting with final kissing balloons was the technique used in all bifurcation lesions. Angiographic success was obtained in all patients. There were no in-hospital deaths or complications. After a 29.8-month (range 8-59) mean follow up period, a myocardial infarction caused by late stent thrombosis occurred in 1 patient and ischemia-driven target vessel revisualization was required in another; however, all patients were alive., Conclusion: In the very elderly patients at excessively high risk for surgery, PCI for ULMCA disease is a suitable alternative with excellent short-term results and acceptable long-term outcomes.

Published
2010

22. Assessment of the trackability, flexibility, and conformability of coronary stents: a comparative analysis.

Author

Rieu R, Barragan P, Garitey V, Roquebert PO, Fuseri J, Commeau P, and Sainsous J

Subjects
Humans, In Vitro Techniques, Materials Testing, Models, Cardiovascular, Prosthesis Design, Blood Vessel Prosthesis, Equipment Failure Analysis, Pliability, Stents, Tensile Strength
Abstract

The efficacy and safety of coronary stent implantation depend on the mechanical features of these devices when deployed in atheromatous lesions of various morphologies. We evaluated the trackability, flexibility, and conformability of 17 coronary stents using specific mechanical bench tests. The quantifications used a dynamometer for assessment of trackability (maximal strength) and flexibility (stiffness) and a 3D optical gauging machine for assessment of conformability (distance between stent and arterial wall in a curvature). The maximal strength (measuring the trackability) ranged respectively from 0.24 +/- 0.06 and 0.38 +/- 0.03 N (Seaquest) to 1.31 +/- 0.42 and 1.34 +/- 0.35 N (Carbostent), concerning respectively curvatures of 90 degrees (P < 0.0001) and 135 degrees (P < 0.0001). The stiffness (measuring the flexibility) ranged from 0.53 +/- 0.16 (Seaquest) to 1.28 +/- 0.10 N/mm (NIR Royal; P < 0.0001). The mean distance between stent and external curvature (external conformability) ranged from 0.15 +/- 0.06 mm (S7) to 0.57 +/- 0.4 mm (NIR Royal; P < 0.0001). The mean distance between stent and internal curve (internal conformability) ranged from 0.26 +/- 0.13 (S7) to 0.44 +/- 0.12 mm (S670; P < 0.0001). These results may influence the choice of a particular stent adapted to a specific coronary anatomy., (Copyright 2003 Wiley-Liss, Inc.)

Published
2003
Full Text
View/download PDF

23. Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures.

Author

Silvestri M, Barragan P, Sainsous J, Bayet G, Simeoni JB, Roquebert PO, Macaluso G, Bouvier JL, and Comet B

Subjects
Adult, Aged, Aged, 80 and over, Coronary Angiography, Coronary Disease diagnostic imaging, Coronary Disease mortality, Female, Follow-Up Studies, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors administration & dosage, Platelet Aggregation Inhibitors adverse effects, Premedication, Survival Rate, Ticlopidine administration & dosage, Ticlopidine adverse effects, Treatment Outcome, Angioplasty, Balloon, Coronary instrumentation, Coronary Disease therapy, Stents
Abstract

Objectives: We sought to evaluate immediate and late outcomes after stenting for left main coronary artery (LMCA) stenosis., Background: Conventional percutaneous transluminal coronary angioplasty (PTCA), for which coronary artery bypass grafting (CABG) has been the gold standard therapy for years, has yielded poor results in unprotected LMCA lesions. The development of coronary stents, together with their dramatic patency improvement provided by new antiplatelet regimens and their validation against restenosis, warrants a reappraisal of angioplasty in LMCA stenosis., Methods: From January 1993 to September 1998, 140 consecutive unselected patients with unprotected LMCA stenosis underwent elective stenting. Group I included 47 high-CABG-risk patients, and group II included 93 low-CABG-risk patients. Ticlopidine without aspirin was routinely started at least 72 h before the procedure and continued for one month. Patients were reevaluated monthly. A follow-up angiography was requested after six months., Results: The procedure success rate was 100%. One-month mortality was 9% (4/47) in group I and 0% in group II. A follow-up angiography was obtained in 82% of cases, and target lesion revascularization was required in 17.4%. One-year actuarial survival was 89% in the first 29 group I patients and 97.5% in the first 63 group II patients., Conclusions: Stenting of unprotected LMCA stenosis provided excellent immediate results, particularly in good CABG candidates. Medium-term results were good, with a restenosis rate of 23%, similar to that seen after stenting at other coronary sites. Stenting deserves to be considered a safe and effective alternative to CABG in institutions performing large numbers of PTCAs.

Published
2000
Full Text
View/download PDF

24. Elastic recoil of coronary stents: a comparative analysis.

Author

Barragan P, Rieu R, Garitey V, Roquebert PO, Sainsous J, Silvestri M, and Bayet G

Subjects
Angioplasty, Balloon, Coronary instrumentation, Equipment Design, Equipment Safety, Evaluation Studies as Topic, Humans, Metals, Pressure, Sensitivity and Specificity, Stress, Mechanical, Temperature, Materials Testing methods, Stents
Abstract

Minimum elastic recoil (ER) has became an essential feature of new coronary stents when deployed in artheromatous lesions of various morphologies. The ER of coronary stent might be an important component of 6-month restenosis rate by minimizing the luminal loss. We evaluated the intrinsic ER of 23 coronary stents with a mechanical test bench. The amount of ER for one size of stent (3.0 mm) was quantified using a 3D optical contactless machine (Smartscope MVP, Rochester, NY). The stents were expanded on their own balloon for the precrimped stents; the uncrimped stents were expended using identical 3.0-mm balloons. Two types of measurements were done without exterior stress and with a 0.2-bar exterior stress, directly on the stent at the end of balloon expansion, immediately after balloon deflation, and then 30 min, 60 min, and 120 min after. ER ranged from 1.54%+/-0.81% (Bestent BES 15) to 16.51%+/-2.89% (Paragon stent) without stress (P<0.01) and from 2.35%+/-1.14% (Bestent BES 15) to 18.34%+/-2.41% (Cook GR2) under 0.2-bar pressure (P<0.0001). Furthermore, there was a significant reduction between the mean result of tubular stents (TS) and coil stents (CS). The results of in vitro mechanical tests may confirm strongly the interest of a minimum ER in the prevention of the 6-month restenosis.

Published
2000
Full Text
View/download PDF

25. Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent.

Author

Zheng H, Barragan P, Corcos T, Siméoni JB, Favereau X, Roquebert PO, Guérin Y, and Sainsous J

Subjects
Adult, Aged, Aged, 80 and over, Angioplasty, Balloon, Coronary, Blood Vessel Prosthesis, Coronary Angiography, Coronary Restenosis diagnostic imaging, Coronary Restenosis prevention & control, Coronary Stenosis diagnostic imaging, Feasibility Studies, Female, Humans, Male, Middle Aged, Prospective Studies, Thrombosis prevention & control, Treatment Outcome, Blood Vessel Prosthesis Implantation instrumentation, Coated Materials, Biocompatible therapeutic use, Coronary Stenosis therapy, Phosphorylcholine therapeutic use, Stents
Abstract

Aims: The BiodivYsio stent is a new stent coated with phosphorylcholine, a biocompatible molecule designed to reduce the formation of thrombus and potentially the risk of restenosis. The feasibility, safety, and efficacy of elective and urgent implantation of this coated coronary stent were prospectively studied., Methods and Results: We studied 224 patients who underwent elective (67%) or bail-out implantation of 303 BiodivYsio stents in 286 lesions. Most lesions (62%) had unfavorable characteristics (type B2 or C) and half of them (50%) had thrombus and/or chronic total occlusion. Clinical follow-up was obtained in all patients at one month and in the first 132 patients at six months. Repeat angiography was undertaken in all patients with recurrent ischemia. Successful stent deployment was achieved in 284 lesions (99.3%). One emergency coronary artery bypass graft (CABG) was required. Angiographic success rate was 98.3% (281/286). There was 1 (0.4%) subacute stent thrombosis associated with Q-wave myocardial infarction and two (0.9%) in-hospital deaths. Reference vessel diameter was 2.82 +/- 0.32 mm. Minimum luminal diameter (MLD) increased from 0.38 +/- 0.25 mm to 2.97 +/- 0.35 mm and diameter stenosis decreased from 83.8 +/- 12.1% to 5.8 +/- 9.7%. Clinical restenosis rate was 6.1% (8/132 patients) at 6-month follow-up. Target vessel revascularization rate at 6-month follow-up was 5.4%., Conclusions: This initial clinical experience indicates that the implantation of stents coated with phosphorylcholine appears to be safe and efficacious in the treatment of complex coronary lesions and is associated with an extremely low target vessel revascularization rate.

Published
1999

26. Radial force of coronary stents: a comparative analysis.

Author

Rieu R, Barragan P, Masson C, Fuseri J, Garitey V, Silvestri M, Roquebert P, and Sainsous J

Subjects
Evaluation Studies as Topic, Humans, Materials Testing, Pressure, Prosthesis Design, Stents
Abstract

High radial force has become an essential feature of new coronary stents. These stents are expected to exhibit sufficient radial force and minimum radial recoil when deployed in atheromatous lesions of various morphologies. The aim of this study was to compare the radial force of 17 coronary stents in vitro (Anglodynamics, ACS Multilink, AVE Micro II and GFX, Bard XT, Biocompatibles PC, Cook GR II, Cordis Crossflex, Hexacath Freedom, Johnson & Johnson PS 153'PS 154, and Crown, Medtronic Wiktor and BeStent BEL-15, Saint-Come SC 1616, Scimed Nir 7 and 9). Two in vitro mechanical tests were performed to assess the stent radial force. The first test measured the deformation of coronary stents in a V-stand by using a deformation controlled by a dynamometer based on a longitudinal generatrix. The precision was of 1 micron. This comparative test highlighted the appreciable variation in behavior of the range of tested stents in terms of resistance to local compression. The line graphs obtained show a very small (and in some cases nonexistent) purely elastic behavior area in the stents, with this result reflecting a small (<0.4 Newtons) range of forces applied to all stents. Above this value, the stents did not return to their size before compression and the line graph remains approximately linear for a long period. It was therefore possible to distinguish between two families of stents on the basis of the presence or absence of this elastic area. In the second test, the stent was deployed in a 3.0-mm elastic tube and a pressure gradient created between the interior and exterior of the tube. The precision was of 50 microns. A typical line graph of the pressure-diameter relationship was recognizable for a given stent. No difference in behavior between the different coronary stents was noted up to 0.3 x 10(5) Pa; subsequently, after 0.3 x 10(5) Pa, sizable deformation differences were visible between the least resistant stent, the BeStent BEL-15, and the most resistant stent, the Crossflex.

Published
1999
Full Text
View/download PDF

27. Coronary artery stenting without anticoagulation, aspirin, ultrasound guidance, or high balloon pressure: prospective study of 1,051 consecutive patients.

Author

Barragan P, Sainsous J, Silvestri M, Simeoni JB, Bayet G, Roquebert PO, Bouvier JL, Comet B, and Quatre JM

Subjects
Adult, Aged, Aged, 80 and over, Anticoagulants therapeutic use, Coronary Angiography, Coronary Vessels drug effects, Female, Follow-Up Studies, Heparin therapeutic use, Humans, Male, Middle Aged, Myocardial Ischemia diagnostic imaging, Myocardial Ischemia drug therapy, Postoperative Complications drug therapy, Postoperative Complications etiology, Postoperative Complications mortality, Prospective Studies, Survival Rate, Thrombosis diagnostic imaging, Thrombosis drug therapy, Thrombosis etiology, Coronary Vessels surgery, Myocardial Ischemia surgery, Platelet Aggregation Inhibitors therapeutic use, Stents adverse effects, Ticlopidine therapeutic use
Abstract

Between March 1994 and November 1995, 1,212 coronary stents were implanted in 1,051 consecutive patients at our institution with the following protocol: daily pre- and poststenting treatment with ticlopidine 500 mg without aspirin, implantation under angiographic guidance, without ultrasound, with semi-compliant balloons inflated at 10 bars. Stenting was indicated after failure of balloon angioplasty (bail-out, dissection, elastic recoil) in 27% of the patients and considered as elective (de novo, restenosis, chronic occlusion, saphenous vein grafts) in 73% of the cases. During the 30-day follow-up period, stent thrombosis occurred in 11 patients (1.0%) and vascular access-site complications in three patients (0.3%). Thirteen patients (1.1%) died, 10 from previous left ventricular failure, 3 (0.3%) from subacute thrombosis. Multivariate analysis revealed that the size of the last balloon used was associated with subacute stent thrombosis Thus, in nonselected patients, placement of coronary stents may be safely achieved without use of warfarin, post procedural heparin, high balloon pressure, or ultrasound guidance. Antiplatelet therapy with ticlopidine and angiographic guidance result in a stent thrombosis rate of 1% and a vascular complication rate of 0.3%.

Published
1997
Full Text
View/download PDF

28. [Pilot study of the efficacy of ticlopidine in early patency of coronary endoprostheses].

Author

Barragan P, Sainsous J, Silvestri M, Bouvier JL, Comet B, Siméoni JB, Villain P, Pietri P, Quatre JM, and Bayet G

Subjects
Adult, Age Factors, Aged, Aged, 80 and over, Coronary Disease surgery, Coronary Thrombosis etiology, Coronary Thrombosis prevention & control, Coronary Vessels pathology, Female, Humans, Male, Middle Aged, Risk Factors, Time Factors, Angioplasty, Balloon, Coronary, Coronary Disease therapy, Graft Occlusion, Vascular prevention & control, Stents, Ticlopidine therapeutic use
Abstract

Subacute thrombosis of coronary stents is the main complication of this technique. The authors studied the outcome of 387 patients and 400 coronary arteries who underwent implantation of 427 stents between December 1989 and February 1994 and followed up one month after the procedure: all patients receive 500 mg of ticlopidine daily from three days before angioplasty throughout the hospital period and continued for at least one month. Anticoagulation with heparin was undertaken by the intravenous route after implantation and relayed with subcutaneous heparin for one week until control coronary angiography performed in the first 300 patients. At one month, 96.9% of patients were free of clinical coronary events. The following major complications were observed: 5 deaths (1.3%), 5 Q wave myocardial infarctions (1.3%); no emergency bypass surgery. The peripheral vascular complication rate was 3.6%. Univariate analysis three risk factors of subacute thrombosis: age (p = 0.0058), arterial diameter of less than 3 mm (p < 0.01) and implantation for occlusive dissection (p = 0.03). Multivariate analysis showed two independent risk factors: age (p = 0.001) and arterial diameter of less than 3 mm (p = 0.01). This pilot study shows a particularly low subacute thrombosis rate in unselected indications with an acceptable level of vascular complications.

Published
1994

29. [Late coronary reperfusion. A possible etiology of post-infarction angina].

Author

Joly P, Bory M, Bonnet JL, Silvestri M, Sainsous J, and Djiane P

Subjects
Adult, Humans, Male, Middle Aged, Myocardial Reperfusion Injury diagnostic imaging, Recurrence, Angina Pectoris etiology, Coronary Angiography, Myocardial Infarction complications, Myocardial Reperfusion Injury physiopathology
Abstract

Late recanalisation of the infarct Related Artery is possible and may cause post-infarction angina. This was observed in 7 male patients who had complete occlusions of an artery with collateral circulation in the immediate post-infarction period. After a symptom-free period of 17 months, angina recurred and repeat angiography showed recanalisation of the occluded artery with regression of the collateral circulation resulting in myocardial ischemia. Myocardial revascularisation was then required.

Published
1991

30. [Coronarography by percutaneous puncture of the axillary artery. Value in arteriopathies of the lower limbs].

Author

Valeix B, Labrunie P, Jahjah F, Monassier JP, Guarino L, Sainsous J, Tournigand P, Ambrosi C, Lévy S, and Gérard R

Subjects
Adult, Aged, Evaluation Studies as Topic, Female, Humans, Male, Middle Aged, Punctures, Arterial Occlusive Diseases diagnostic imaging, Axillary Artery, Cardiac Catheterization methods, Coronary Angiography, Leg blood supply
Abstract

Coronary angiography by a percutaneous femoral approach using the Judkins-Bourassa technique with special preformed catheters is widely used. This approach is potentially dangerous or impossible in patients with severe lower limb arteriosclerosis even after operation and so the investigation has to be done by Sones' technique (denudation of the humeral artery). There is, however, another upper limb approach which does not involve arterial denudation: percutaneous right or left axillary artery catheterisation. This paper reports the experience of a multicentre study of this method in 105 patients. This study is of interest as an arterial catheter introducer was used which, does not compress the artery, prevents bleeding when the catheter has to be changed and reduced the risk of thromboses or laceration of the axillary artery. 73 of the 105 patients had lower limb arteriosclerosis 5 had aortic aneurysms and 1 patient had a previous history of femoral artery embolism. There was a primary indication for this approach in 21 cases. The left axillary artery was used in 83 cases (79%) and the right axillary artery in 22 cases (21%). The coronary catheters were those usually used with the femoral approach. The left side was chosen preferentially as it avoided the brachiocephalic trunk and facilitated the catheterisation of the coronary ostia and of aorto-coronary bypass grafts. Selective catheterisation of the left coronary artery was achieved in 21 out of 22 cases (95%) and of the right coronary artery in all 22 cases (100%) by the right axillary route. Both left and right coronary arteries were selectively catheterised in all cases by the left axillary approach.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1984

31. [Chemical blockade of the cardiac autonomic nervous system. Effects on the coronary arterial vasomotor activity].

Author

Bory M, Dayan-Benattar N, Sainsous J, Djiane P, and Serradimigni A

Subjects
Adult, Aged, Blood Pressure drug effects, Drug Therapy, Combination, Electrocardiography, Female, Heart diagnostic imaging, Heart Rate drug effects, Humans, Male, Middle Aged, Radionuclide Imaging, Atropine therapeutic use, Autonomic Nerve Block, Coronary Vasospasm drug therapy, Ethanolamines therapeutic use, Heart innervation, Labetalol therapeutic use
Abstract

The results of cardiac plexectomy in spastic angina are controversial. This study was undertaken to evaluate the effects of blocking the cardiac autonomic nervous system (CANS) in this syndrome in 61 patients presenting with chest pain and angiographically normal coronary arteries. All patients underwent a methyl-ergometrine provocation test with a sequential protocol. They were then divided into two groups: Group 1 (13 patients): positive response to ergometrine. Group 2 (48 patients): negative response to ergometrine. Three sub-groups were identified: 2: 1: 9 patients with coronary spasm demonstrated by another method: 2: 2: 6 patients with myocardial infarction: 2: 3: 33 patients with chest pain alone. The results of these tests were compared with those obtained after blocking the CANS by intravenous injection over 3 minutes of an alpha and beta-blocker (labetalol 2 mg/kg) and a parasympathetic blocker (Atropine. 0.04 mg/kg). The CANS blockade was confirmed by two facts: the basal heart rate of 66.38 +/- 9.91 rose to ots intrinsic rate of 89.76 +/- 10.5 (p less than 0.01) and remained at that rate after ergometrine and trinitrate administration and myocardial ischaemia; changes in blood pressure were greater after CANS blockade: + 30.62 +/- 16.13 mmHg instead of + 8.62 +/- 0.33 mmHg after ergometrine (p less than 0.01) and -43.16 +/- 16.32 mmHg instead of -25.16 +/- 3.64 mmHg after trinitrate (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1985

32. [Intravenous streptokinase versus heparin in the acute phase of myocardial infarction. Randomized prospective study in southeast France].

Author

Sainsous J, Bonnet JL, and Serradimigni A

Subjects
Aged, Angiography, Electrocardiography, Female, Fibrinogen analysis, France, Heart Ventricles physiopathology, Humans, Infusions, Intravenous, Male, Middle Aged, Myocardial Infarction mortality, Prospective Studies, Random Allocation, Streptokinase administration & dosage, Heparin therapeutic use, Myocardial Infarction drug therapy, Streptokinase therapeutic use
Published
1986
Full Text
View/download PDF

33. [Immediate coronary angioplasty in the acute phase of myocardial infarction. French multicenter study: December 1983].

Author

Valeix B, Labrunie P, Marco J, Puel J, Bory M, Sainsous J, Monassier JP, Heitz A, Gaspard P, and Guarino L

Subjects
Adult, Aged, Electrocardiography, Evaluation Studies as Topic, Female, Fibrinolysis, Humans, Male, Middle Aged, Myocardial Infarction physiopathology, Time Factors, Angioplasty, Balloon, Myocardial Infarction therapy
Abstract

Following the introduction of intracoronary thrombolysis in the acute phase of myocardial infarction (AMI), transcutaneous coronary angioplasty (TCA) was originally conceived as a logical complementary procedure to treat residual stenosis and so prevent the frequent post-thrombolysis reocclusion (20-30 p. 100 of cases). With increasing experience TCA of first intent appeared rational, more rapid and effective, ensuring coronary recanalisation (CR), suppression of residual stenosis and the prevention of reocclusion in the same procedure with with the objective of reducing the number of coronary bypass grafts (CBG) in patients with single vessel disease. A French multicentre study of 22 cases was organised by 9 centres. The average period between onset of symptoms and intervention was 2 hours 10 mins (range 30 mins-5 hours 30 mins). The average duration of the procedure was only 30 mins. 16 patients had anterior and 6 patients inferior AMI. Coronary angiography showed 12 occlusions (54.5 p. 100) and 10 sub-occlusions with 6 cases of delayed opacification. All patients had successful initial TCA with no major complications. The arterial occlusions decreased from 100 p. 100 to 31 p. 100 and the subocclusions from 94 to 12 p. 100. 2 patients died in the hospital period, one at the 48th hour of controlateral AMI and the other one at the 5th day of reocclusion. Three patients developed reocclusion at the site of the original TCA. Complete regression of ECG changes was observed in 31.8 p. 100 of cases. Complete recovery of normal left ventricular function was observed in 8 of the 17 patients who underwent follow-up investigations (47 p. 100 of cases).(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1985

34. [Medical treatment of ilio-caval venous thrombosis].

Author

Serradimigni A, Mathieu P, Sainsous J, Chiche G, and Egré A

Subjects
Adult, Aged, Female, Heparin adverse effects, Heparin therapeutic use, Humans, Male, Middle Aged, Streptokinase adverse effects, Streptokinase therapeutic use, Urokinase-Type Plasminogen Activator adverse effects, Urokinase-Type Plasminogen Activator therapeutic use, Iliac Vein, Thrombosis drug therapy, Venae Cavae
Abstract

120 patients with ilio-caval thrombosis were managed medically. 55 patients were given heparin (5 mg/Kg/day for 15 days), 50 patients received streptokinase (loading dose 250,000 u; maintenance dose 100,000 m/h for 48 hours) and 15 patients had urokinase (112,500 u/h for 44 hours). Thrombolytic therapy was prescribed, in the absence of contraindications, for patients below 70 year of age: other patients were treated with heparin. The results were assessed by venography performed before and after treatment: success was defined as the complete disappearance of the thrombus of disobliteration of the ilio-caval axis. The overall success rate was 32%, with 68% failures. Success was higher with streptokinase (50%) than with heparin (20%) or urokinase (13%). The site, extension ans aetiology of the thrombosis did not affect the results. On the other hand, two other factors seemed to play an important role: - the duration of thrombosis: this only affected the streptokinase group; 23 of the 25 successes were obtained in patients treated before the tenth day. The results were unaffected by the duration of the thrombosis in the heparin group; - the biological effectiveness of therapy: 7 out of the 11 successes in the heparin group had been constantly well anticoagulated; there were only 4 successes out of 38 patients in whom the biological effectiveness had been intermittent. There were 21 successes out of 32 patients treated by streptokinase with serum fibrin levels of less than 1 g. There were only 4 successes in the 18 other cases. The incidence of haemorrhage was identical in the 3 groups. Embolism was slightly commoner in the streptokinase (3) than in the heparin group (2).

Published
1981

35. Evidence for isosorbide dinitrate (ISDN) promoting effect on prostacyclin release by the lung and prostacyclin implication in ISDN-induced inhibition of platelet aggregation in humans.

Author

Rolland PH, Bory M, Leca F, Sainsous J, Gueydon E, Juhan I, Serradimigni A, and Cano JP

Subjects
6-Ketoprostaglandin F1 alpha blood, Adenosine Diphosphate pharmacology, Aged, Coronary Disease blood, Dinoprost, Dinoprostone, Eicosanoic Acids blood, Humans, Lung drug effects, Male, Middle Aged, Prostaglandins E blood, Prostaglandins F blood, Thromboxane B2 blood, Epoprostenol blood, Isosorbide Dinitrate pharmacology, Lung metabolism, Platelet Aggregation drug effects
Abstract

We investigated thromboxane B2 (TxB2), 6-keto-PGF1 alpha (6KPGF1 alpha reflecting prostacyclin), PGE2 and PGF2 alpha plasma levels; TxB2, PGE2 and PGF2 alpha platelet production and platelet aggregation response in ascending aorta (reflecting trans-pulmonary difference) and in venous coronary sinus (reflecting transcardiac difference) simultaneously in patients with ischemic heart disease, before and after right-atrial administration of 3 mg ISDN bolus. Transcardiac differences were scarce before as well as after ISDN administration. In aortic blood, ISDN administration into the right atria resulted in a significant increase in prostacyclin and PGF2 alpha plasma levels (472% and 242%, respectively), a decrease of both PGE2 plasma level (-173%) and PGE2 platelet production (-485%) and a marked lowering of platelet aggregation response to ADP, concomittantly. In contrast, TxB2-related features were poorly affected by ISDN. In coronary sinus blood, the aortic increase in 6KPGF1 alpha and PGF2 alpha plasma levels was detected to a lower extent whereas the characteristics of platelet aggregation had returned to control levels. By contrast, PGE2 plasma level (-191%) and PGE2 platelet production (-133%) were lower than prior ISDN administration. The results we report here, strongly support the view that ISDN promotes release of prostacyclin and PGF2 alpha from the lung and inhibit PGE2 production. These prostanoids may be responsible for the concomittant platelet reactivity lowering, thus providing a basis for understanding how ISDN might relieve myocardial ischemia favoring prostanoid mediated vasodilation and inhibition of platelet reactivity.

Published
1984
Full Text
View/download PDF

36. [Simultaneous appearance of precordial pain and effort-induced left bundle branch block. A study of 6 patients with normal coronary angiography].

Author

Bory M, Karila P, Sainsous J, Cohen S, Djiane P, Paulin R, and Serradimigni A

Subjects
Adult, Atropine therapeutic use, Bundle-Branch Block diagnosis, Bundle-Branch Block drug therapy, Coronary Angiography, Echocardiography, Exercise Test, Female, Humans, Isoproterenol therapeutic use, Male, Middle Aged, Propranolol therapeutic use, Radioisotopes, Thallium, Bundle-Branch Block complications, Pain, Thorax
Abstract

6 patients, 4 men and 2 women, aged 38 to 60 years, were hospitalised for chest pain on effort, labelled as angina. The resting electrocardiogram was normal, except in 2 cases with incomplete left bundle branch block. Exercise stress testing induced simultaneous chest pain and complete left bundle branch block (LBBB) (at a rate of 15 to 160 beats/min, mean 115). The pain lasted as long as the LBBB was present and eased as it disappeared. All patients had normal coronary angiography and negative provocative tests of coronary spasm with atrial stimulation (4 cases), isoprenaline test (2 cases), atropine injection (2 cases) and nitroglycerin (1 case). A 2D echocardiogram performed in all the patients, showed no signs of myocardial disease. Myocardial perfusion on effort was studied by Thallium 201 scintigraphy in all 6 patients. There were no perfusion defects. An exercise stress test was performed after beta-blocker treatment in 3 patients. LBBB appeared each time and the pain was always present. The induction of bradycardia with propranolol (5 cases) or verapamil (3 cases) did not reduce the frequency of chest pain. No serious complications were observed during follow-up (myocardial infarction, death). The syndrome of painful LBBB is not related exclusively to tachycardia. Myocardial ischaemia does not seem to be the underlying mechanism judged by the negative thallium studies.

Published
1985

38. [Genesis of myocardial infarction].

Author

Bory M, Sainsous J, Bénichou M, Djiane P, and Serradimigni A

Subjects
Coronary Circulation, Coronary Disease physiopathology, Coronary Vessels physiopathology, Humans, Myocardial Infarction etiology, Myocardium metabolism, Oxygen Consumption, Platelet Aggregation, Vasoconstriction, Myocardial Infarction physiopathology
Abstract

The causes of myocardial infarction (MI) are complex and multiple and may eventually be associated. Two main types of mechanism are thought to be implicated: Functional mechanisms: these are operative in prolonged angina: the difference between MI and angina pectoris is related to the duration of these phenomena and to the resistance of the myocardial cells to anoxia: unsatisfied increase in myocardial oxygen demand, as for example in exercise-induced myocardial infarction; sudden reduction in oxygen supply due to an excessive fall in coronary flow, inadequate vasodilatation, platelet aggregation or coronary spasm. Priviledged cases are presented to demonstrate the reality of these phenomena. These mechanisms can sometimes cause MI by themselves, even when the coronary arteries are normal (5% of cases), and nearly always complicate and aggravate obstruction due to an atheromatous plaque. Organic obstructive lesions: coronary obstruction observed in about 2/3 of cases, sometimes caused by rupture of an atheromatous plaque, is usually the result of coronary thrombosis. The predominance of this mechanism is an argument in favour of it being the principal cause of MI. However, other workers believe that thrombosis is a secondary phenomenon induced by stasis, functional mechanisms or severe stenosis. The clot itself would then cause obstruction even if the primary cause were to regress. Irrespective of the roles of each of these factors it would appear logical to treat the functional mechanisms assumed to be responsible and the coronary thrombosis before the myocardial cells are destroyed by the anoxia.

Published
1984

39. [Repeated coronarographies in 122 medically treated patients].

Author

Sainsous J, Baragan P, Bénichou M, Bory M, and Serradimigni A

Subjects
Adult, Aged, Arteriosclerosis diagnostic imaging, Arteriosclerosis physiopathology, Coronary Disease drug therapy, Coronary Disease physiopathology, Female, Humans, Male, Middle Aged, Time Factors, Coronary Angiography, Coronary Disease diagnostic imaging
Abstract

122 patients treated medically 115 men and 7 women aged 51.9 +/- 8.51 years (range 32 to 79 years) underwent repeat coronary angiography 34 +/- 26 months (1 month-11 years) after the initial investigation Patients with normal coronary arteries were excluded. The repeat investigation was performed for aggravation and persistance of symptoms in 74 cases, myocardial infarction in 14 cases, with a view to aortocoronary bypass in 23 cases, for cardiac failure in 8 cases and for ventricular arrhythmias in 3 cases. Three groups of patients could be distinguished: Group I: the coronary angiography was unchanged (41 patients, 33.6 p. 100). The interval between the two investigations was 30.7 +/- 24.8 months. Group II: the coronary lesions had regressed in 12 patients (9.8 p. 100). The interval between the two investigations was 29.4 +/- 23 months. The degree of stenosis was reduced in 6 cases; recanalisation of an occluded artery was demonstrated in 3 cases; coronary spasm was diagnosed in 3 cases. Paradoxically, 4 patients had developed lesions on other coronary segments. Group III: the coronary lesions had progressed in 69 patients (56.6 p. 100). The interval between the two investigations was 36.8 +/- 26.9 months. The progression was observed on a pre-existing stenosis in 51 cases and on an initially normal segment in 34 cases. Left ventricular function had worsened in 21.7 p. 100 of patients compared to only 5.6 p. 100 of patients in groups I and II (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1985

41. [Prognostic value of coronary spasm threshold determined by the ergometrine test].

Author

Bory M, Marie P, Calaf R, Sainsous J, Djiane P, and Serradmigni A

Subjects
Coronary Vasospasm chemically induced, Coronary Vasospasm drug therapy, Diltiazem therapeutic use, Humans, Prognosis, Time Factors, Verapamil therapeutic use, Coronary Vasospasm physiopathology, Ergonovine
Abstract

The prognosis of spastic angina is difficult to determine. The object of this study was to try to evaluate the prognosis of coronary spasm on the results of provocative, ergometrine testing. Out of 708 patients with angiographically normal or near-normal coronary arteries undergoing the ergometrine test for assessment of chest pain, 78 patients with positive results were retained for study. The threshold of spasm was established in every case: this was defined as the quantity of ergometrine per kilogramme body weight required to provoke spasm. The values ranged from 1 to 12.5 micrograms/kg (average 7.58 micrograms/kg +/- 3.84). The reproducibility of the ergometrine test appeared to be very satisfactory. In the short term, only 4 out of 32 tests became negative. The test remained positive in 28 cases and the mean value of the threshold of spasm did not change significantly (5.64 +/- 3.27 to 5.52 +/- 3.18 micrograms/kg). In the long term only 2 out of 18 tests became negative. The test remained positive in 16 cases and the mean value of the threshold of spasm did not change significantly (5.68 +/- 2.96 to 6.58 +/- 3.11 micrograms/kg). The ergometrine test with a reference threshold of positivity of 5 micrograms/kg is doubly useful: this threshold value helps predict a good response to calcium inhibitor drugs: the threshold of spasm was less than this value in 6 of the 41 patients whose tests became negative after diltiazem therapy, and in 12 of 14 patients in whom the test remained positive (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1984

42. [Spasm, stenosis and thrombosis. Their role in the genesis of myocardial infarction].

Author

Bory M, Sainsous J, Savin B, Bénichou M, Djiane P, and Serradimigni A

Subjects
Adult, Arterial Occlusive Diseases physiopathology, Coronary Angiography, Coronary Disease diagnostic imaging, Coronary Vasospasm diagnostic imaging, Electrocardiography, Humans, Male, Coronary Disease physiopathology, Coronary Vasospasm physiopathology, Myocardial Infarction physiopathology
Abstract

A 42 year old patient underwent coronary angiography 3 hours after the onset of inferior myocardial infarction with the object of local thrombolysis therapy. Complete proximal obstruction of the right coronary artery was relieved mechanically by the catheter. This was associated with a return of the ST segment to the isoelectric line but Q waves persisted in Lead III and AVF. A second injection showed 70 p. 100 stenosis at the site of the obstruction and the radiolucent appearances of thrombus below it. This was followed by 4 successive periods of ST elevation as the right coronary artery reoccluded. These phenomena were relieved by injection of nitroglycerine suggesting a spastic mechanism. The radiolucent image of thrombus disappeared and was replaced by amputation of a distal branch of the right coronary artery. Further coronary opacification showed good run-off beyond the stenosis and reappearance of the distal branch. This case suggests that three factors played a role in the mechanism of infarction: stenosis accompanied by spasm and thrombosis.

Published
1982

Catalog

Books, media, physical & digital resources
See catalog results